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PURINE-BASED TRAZOLES

SUMMARY OF THE INVENTION

RELATED APPLICATION

This application relates to substituted purine-based triaz
oles that can inhibit protein kinases, such as cyclin-dependent
kinase (CDK), G proteins and polymerases, as well as phar
maceutical compositions comprising the same, and methods
for formulating or using the same to treat diseases or disorders
associated with protein kinases, G proteins and plymerases.
In one embodiment, the Substituted purine-based analog
can include the following formula (I):

This application is a National Phase filing of PCT/US2011/
055962, filed Oct. 12, 2011, which claims priority from U.S.
Provisional Application No. 61/392.237, filed Oct. 12, 2010,
the subject matter of which are incorporated herein by refer
ence in their entirety.
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TECHNICAL FIELD

This application relates to purine-based triazoles and to the
use of the purine-based triazoles as protein kinase inhibitors
and to treat diseases or disorders associated with protein

(I)
15

kinases.

R
BACKGROUND OF THE INVENTION

Initiation, progression, and completion of the mammalian
cell cycle are regulated by various cyclin-dependent kinase
(CDK) complexes, which are critical for cell growth. CDKs
are highly conserved among eukaryotic species. Higher
eukaryotic cells contain several isoforms of CDKs that
become activated in specific phases of the cell cycle. CDKs
consist of a catalytic subunit, the prototype of which is CDC2,
and a regulatory subunit (cyclin). Six human CDK proteins
have been described so far (see, Meyerson, M., et al. (1992),
EMBO J., 11:2909-2917; Meyerson, M., et al. (1994), Mol.

N

25

30

Cell. Biol., 14:2077-2086; and Van den Heuvel, S., et al.

(1993), Science, 262:2050-2054), namely, CDK1 (also
known as CDC2) and CDK2-6. With the exception of CDK3,
for which the regulatory cyclin has not yet been identified, all
these CDK proteins are regulated by the transient association
with one member of the cyclin family, i.e., cyclin A (CDC2,
CDK2), B1-B3 (CDC2), D1-D3 (CDK2, CDK4, CDK5,
CDK6), E (CDK2). Each step of the cell cycle is thought to be
regulated by such CDK complexes: G1/S transition (CDK2/
cyclin E, CDK3/unknown cyclin, CDK4/cyclin D1-D3,
CDK6/cyclin D3), S phase (CDK2/cyclin A), G2 (CDC2/
cyclin A), G2/M transition (CDC2/cyclins B).
The function of CDKs is to phosphorylate and thus activate
or deactivate certain proteins, including e.g., retinoblastoma
proteins, lamins, histone H1, and components of the mitotic
spindle. The catalytic step mediated by CDKs involves a
phospho-transfer reaction from ATP to the macromolecular
enzyme Substrate. Several groups of compounds (reviewed in
e.g., Fischer, P. M. Curr. Opin. Drug Discovery Dev. 2001, 4,
623-634) have been found to possess anti-proliferative prop
erties by virtue of CDK-specific ATP antagonism.
WO 98/05335 discloses 2.6.9-trisubstituted purine deriva
tives that are selective inhibitors of cell cycle kinases. Such
compounds are useful in the treatment of autoimmune disor
ders, e.g., rheumatoid arthritis, lupus, type I diabetes, mul
tiple Sclerosis; treating cancer, cardiovascular disease. Such
as restenosis, host V graft disease, gout, polycystic kidney
disease and other proliferative diseases whose pathogenesis
involves abnormal cell proliferation.
WO99/07705 discloses purine analogues that inhibit inter
alia protein kinases, G-proteins and polymerases. More spe
cifically, WO 705 discloses methods of using such purine
analogues to treat cellular proliferative disorders and neuro
degenerative diseases.
WO97/20842 also discloses purine derivatives displaying
antiproliferative properties, which are useful in treating can
cer, psoriasis, and neurodegenerative disorders.
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or a pharmaceutically acceptable salt thereof, wherein
where R is a hydrophobic, substituted or unsubstituted,
aryl, cyclic, or heterocyclic group;
where R and R independently represent Substituents
Selected from the group consisting of hydrogen, halogen
atom, C1-C4 alkyl, C-C2 alkenyl, C2-C2a alkynyl,
Cs-Co aryl, C-C alkaryl, C-C aralkyl, silyl,
hydroxyl, Sulfhydryl, C-C alkoxy, C-C alkeny
loxy, C-C alkynyloxy, Cs-Co aryloxy, acyl, C-C
alkylcarbonyl (—CO-alkyl). Co-Co arylcarbonyl
(—CO-aryl)), acyloxy ( O-acyl), C-C alkoxycarbo
nyl (-(CO)—O-alkyl). Co-Co aryloxycarbonyl
(—(CO)—O-aryl), C-C alkylcarbonato (-O(CO)—O-alkyl), C-C arylcarbonato ( O—(CO)—
O-aryl), carboxy ( -COOH), carboxylato (-COO),
carbamoyl (-(CO)—NH), mono-(C-C alkyl)-Sub
stituted carbamoyl (—(CO)—NH(C-C alkyl)), di
(C-C alkyl)-substituted carbamoyl (—(CO)—N(CC
alkyl)), mono-substituted arylcarbamoyl
(—(CO). NH-aryl), thiocarbamoyl (—(CS) NH),
carbamido ( NH-(CO) NH), cyano ( CN), iso
cyano ( NC), cyanato ( O—CN), isocyanato (ONC),
isothiocyanato (—S CN), azido ( N=N*—N),
formyl (—(CO)—H), thioformyl ( (CS)—H), amino
(—NH), mono- and di-(C-C alkyl)-substituted
amino, mono- and di-(C-C aryl)-substituted amino,
C-C alkylamido (—NH-(CO)-alkyl). Co-Co aryla
mido ( NH (CO)-aryl), imino, alkylimino,
arylimino, nitro ( NO), nitroso ( NO), sulfonic acid
(—SO-OH), sulfonato ( SO O), C-C alkylsul
fanyl ( S-alkyl), arylsulfanyl, C-C alkylsulfinyl
(—(SO)-alkyl), Cs-Co arylsulfinyl (—(SO)-aryl),
C-C alkylsulfonyl (—SO-alkyl), Cs-Co arylsulfo
nyl ( SO-aryl), phosphono ( P(O)(OH)), phospho
nato ( P(O)(O ),), phosphinato ( P(O)(O)), phos
pho ( PO), and phosphino ( -PH), and where each
R and R being independently unsubstituted or Substi
tuted where appropriate by one or more —OH, halogen,
amino or alkyl groups.
In some embodiments, R is a fluorinated aryl, cyclic, or
heterocyclic group. In other embodiments R and R are each
independently a halogen atom, C-C alkyl, C-C alkenyl,
C2-C2-alkynyl, Ca-Cao aryl, C-C2-alkaryl, C-C2a aralkyl,
or an R. NH-, R. NH-NH , NH R NH or
R. NH R' NH radical, in which Ra represents a
straight- or branched-chain, Saturated or unsaturated alkyl
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radical, an aryl or cycloalkyl radical or a heterocyclic ring and
R" represents a straight- or branched-chain, Saturated or
unsaturated alkylene group or an arylene or cycloalkylene
group, where R and Reach contain 1 to 8 carbonatoms, and
where each R and R can be independently unsubstituted or
substituted, where appropriate, by one or more —OH, halo
gen, amino or alkyl groups.
Another embodiment of the application relates to a method
of inhibiting a protein selected from the group consisting of
protein kinases, G proteins and polymerases by contacting the
protein with a substituted purine-based triazole. In some
embodiments, the protein is a protein kinase. In other
embodiments, the protein kinase is a cyclin-dependent
kinase. In still other embodiments, the cyclin-dependent
kinase is a member selected from the group consisting of
CDK1 (CDC2), CDK2, CDK3, CDK4, CDK5, CDK6,
CDK7 and CDK8 and, in particular CDK5.
Yet another embodiment of the application relates to the
use of the Substituted purine-based triazole in treating a dis
ease process featuring abnormal cell cycle or cellular prolif
eration, including, but not limited to, abnormal stimulation of
endothelial cells (e.g., atherosclerosis), neoplastic disorders,
Solid tumors and tumor metastasis, benign tumors, for
example, hemangiomas, acoustic neuromas, neurofibromas,
trachomas, and pyogenic granulomas, cancer, Vascular mal
functions, abnormal wound healing, inflammatory and
immune disorders, Bechet's disease, gout or gouty arthritis,
abnormal angiogenesis accompanying, for example, rheuma
toid arthritis, psoriasis, diabetic retinopathy, other ocular
angiogenic diseases, such as retinopathy of prematurity (ret
rolental fibroplastic), macular degeneration, corneal graft
rejection, neuroscular glaucoma and Oster Webber syn
drome, alopecia, fungal, parasitic and viral infections, such as
cytomegaloviral infections, neurological disorders, stroke
neurofibromatosis, endotoxic shock, hypertrophic scar for
mation, inflammatory bowel disease, transplant rejection,
vascular Smooth muscle cell proliferation associated with
atherosclerosis, pulmonary fibrosis, arthritis, glomerulone
phritis, restenosis following angioplasty or vascular Surgery,
and other post-Surgical Stenosis and restenosis.
In some embodiments, the disease or disorder treated by
the Substituted purine-based triazole is a neurological disor
der. In other embodiments, the disease or disorder treated by
the substituted purine-based triazole is a neoplastic disorder.

4
GenDock simulations; Region A is the highest scoring site in
accordance with co-crystal structure. 1UNL.
FIG. 6 illustrates an expanded view of the Roscovitine
CDK5/p25 complex showing the X-ray structure (1UNL)
superimposed on the DarwinDock/GenDock simulated struc
ture.

FIG. 7 illustrates an expanded view of the Compound
7-CDK5/p25 complex, showing hydrogen bonds to Lys89,
Ile10, Asn144 and Gln130.
10

DETAILED DESCRIPTION

For convenience, certain terms employed in the specifica
tion, examples, and appended claims are collected here.
15

The articles “a” and “an are used herein to refer to one or

to more than one (i.e., to at least one) of the grammatical
object of the article. By way of example, “an element’ means
one element or more than one element.
25

The terms “comprise.” “comprising.” “include.” “includ
ing,” “have.” and “having are used in the inclusive, open
sense, meaning that additional elements may be included.
The terms "such as”, “e.g., as used herein are non-limiting
and are for illustrative purposes only. “Including and
“including but not limited to are used interchangeably.
The term 'or' as used herein should be understood to mean

30

35

“and/or, unless the context clearly indicates otherwise.
It will be noted that the structure of some of the compounds
of the application include asymmetric (chiral) carbon atoms.
It is to be understood accordingly that the isomers arising
from such asymmetry are included within the scope of the
invention, unless indicated otherwise. Such isomers can be

obtained in Substantially pure form by classical separation
techniques and by Stereochemically controlled synthesis. The
compounds of this application may exist in Stereoisomeric
form, therefore can be produced as individual stereoisomers
40

or as mixtures.

“Isomerism” means compounds that have identical
molecular formulae but that differ in the nature or the
45

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other features of the application will
become apparent to those skilled in the art to which the
application relates upon reading the following description
with reference to the accompanying drawings, in which:
FIG. 1 illustrates fluorescence microscopy images showing
the time-dependent PI uptake in hippocampal slices exposed
to 5 uMoligomers.
FIG. 2 illustrates a chart showing PI uptake responses
between groups.
FIG.3 illustrates fluorescence microscopy images showing
the relative PI uptake in hippocampal slices incubated with
various compounds (1 uM; 1 h) followed by AB oligomers (5
uM; 48 h).
FIG. 4 illustrates a chart showing PIuptake responses. Data
were expressed as the means-S.E. (n=4). Differences
between groups were examined for statistical significance
using one-way analysis of variance with an unpaired Students
t-test (*: p<0.05; #: p<0.05, #: p<0.01).
FIG.5 illustrates a schematic view of potential Roscovitine
binding regions in CDK5/p25 obtained from DarwinDock/

Unless defined otherwise, all technical and scientific terms

used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this application
belongs.

sequence of bonding of their atoms or in the arrangement of
their atoms in space. Isomers that differ in the arrangement of
their atoms in space are termed “stereoisomers'. Stereoiso
mers that are not mirror images of one another are termed
"diastereoisomers', and stereoisomers that are non-Superim
posable mirror images are termed “enantiomers', or some
times optical isomers. A carbonatom bonded to four noniden

50

tical substituents is termed a "chiral center'.

55

“Chiral isomer means a compound with at least one chiral
center. It has two enantiomeric forms of opposite chirality and
may exist either as an individual enantiomer or as a mixture of
enantiomers. A mixture containing equal amounts of indi
vidual enantiomeric forms of opposite chirality is termed a
“racemic mixture'. A compound that has more than one chiral
center has 2n-1 enantiomeric pairs, where n is the number of
chiral centers. Compounds with more than one chiral center
may exist as either an individual diastereomer or as a mixture

60

of diastereomers, termed a "diastereomeric mixture'. When

one chiral center is present, a stereoisomer may be character
ized by the absolute configuration (R or S) of that chiral
center. Absolute configuration refers to the arrangement in
space of the substituents attached to the chiral center. The
65

substituents attached to the chiral center under consideration

are ranked in accordance with the Sequence Rule of Cahn,
Ingold and Prelog. (Cahn et al. Angew. Chem. Inter. Edit.

US 8,969,556 B2
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1966, 5,385; errata 511; Cahn et al., Angew. Chem. 1966,78,
413: Cahn and Ingold, J Chem. Soc. 1951 (London), 612:
Cahn et al., Experientia 1956, 12, 81; Cahn, J., Chem. Educ.
1964, 41, 116).

“Geometric Isomers' means the diastereomers that owe
their existence to hindered rotation about double bonds.

These configurations are differentiated in their names by the
prefixes cis and trans, or Z and E, which indicate that the
groups are on the same or opposite side of the double bond in
the molecule according to the Cahn-Ingold-Prelog rules.
Further, the structures and other compounds discussed in
this application include all atropic isomers thereof. 'Atropic
isomers' area type of stereoisomer in which the atoms of two
isomers are arranged differently in space. Atropic isomers
owe their existence to a restricted rotation caused by hin
drance of rotation of large groups about a central bond. Such
atropic isomers typically exist as a mixture, however as a
result of recent advances in chromatography techniques, it
has been possible to separate mixtures of two atropic isomers

5

10

15

transdermal. Subcutaneous, intravenous, intramuscular, intra

in select cases.

The terms “crystal polymorphs' or “polymorphs' or “crys
tal forms' means crystal structures in which a compound (or
salt or solvate thereof) can crystallize in different crystal
packing arrangements, all of which have the same elemental
composition. Different crystal forms usually have different
X-ray diffraction patterns, infrared spectra, melting points,
density hardness, crystal shape, optical and electrical proper
ties, stability and solubility. Recrystallization solvent, rate of
crystallization, storage temperature, and other factors may
cause one crystal form to dominate. Crystal polymorphs of
the compounds can be prepared by crystallization under dif

25

The term “immediate release' is defined as a release of

35

compound from a dosage form in a relatively brief period of
time, generally up to about 60 minutes. The term “modified
release' is defined to include delayed release, extended
release, and pulsed release. The term “pulsed release' is
defined as a series of releases of drug from a dosage form. The

As defined herein, the term "derivative', refers to com

term “sustained release' or “extended release' is defined as

triazoles and have formula I as a common core.

The term “bioisostere” refers to a compound resulting from
the exchange of an atom or of a group of atoms with another,
broadly similar, atom or group of atoms. The objective of a
bioisosteric replacement is to create a new compound with
similar biological properties to the parent compound. The
bioisosteric replacement may be physicochemically or topo
logically based. Examples of carboxylic acid bioisosteres
include acyl Sulfonimides, tetrazoles, Sulfonates, and phos
phonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147
3176 (1996).
The phrases “parenteral administration' and “adminis
tered parenterally are art-recognized terms, and include
modes of administration other than enteral and topical admin
istration, Such as injections, and include, without limitation,
intravenous, intramuscular, intrapleural, intravascular, intra
pericardial, intraarterial, intrathecal, intracapsular, intraor
bital, intracardiac, intradermal, intraperitoneal, transtracheal,
Subcutaneous, Subcuticular, intra-articular, Subcapsular, Sub
arachnoid, intraspinal and intrastemal injection and infusion.
The term “treating is art-recognized and includes inhibit
ing a disease, disorder or condition in a subject, e.g., imped
ing its progress; and relieving the disease, disorder or condi
tion, e.g., causing regression of the disease, disorder and/or
condition. Treating the disease or condition includes amelio
rating at least one symptom of the particular disease or con
dition, even if the underlying pathophysiology is not affected.
The term “preventing is art-recognized and includes stop
ping a disease, disorder or condition from occurring in a
Subject, which may be predisposed to the disease, disorder
and/or condition but has not yet been diagnosed as having it.

peritoneal, intranasal, and the like. Dosage forms for the
topical or transdermal administration of a compound of this
invention include powders, sprays, ointments, pastes, creams,
lotions, gels, Solutions, patches and inhalants. In a preferred
embodiment, the active compound is mixed under sterile
conditions with a pharmaceutically acceptable carrier, and
with any preservatives, buffers, or propellants that are
required.
The term “flash dose' refers to compound formulations
that are rapidly dispersing dosage forms.

30

ferent conditions.

pounds that have a common core structure, and are substituted
with various groups as described herein. For example, all of
the compounds represented by formula I are purine-based

6
Preventing a condition related to a disease includes stopping
the condition from occurring after the disease has been diag
nosed but before the condition has been diagnosed.
A "pharmaceutical composition' is a formulation contain
ing the disclosed compounds in a form Suitable for adminis
tration to a Subject. In a preferred embodiment, the pharma
ceutical composition is in bulk or in unit dosage form. The
unit dosage form is any of a variety of forms, including, for
example, a capsule, an IV bag, a tablet, a single pump on an
aerosol inhaler, or a vial. The quantity of active ingredient
(e.g., a formulation of the disclosed compound or salts
thereof) in a unit dose of composition is an effective amount
and is varied according to the particular treatment involved.
One skilled in the art will appreciate that it is sometimes
necessary to make routine variations to the dosage depending
on the age and condition of the patient. The dosage will also
depend on the route of administration. A variety of routes are
contemplated, including oral, pulmonary, rectal, parenteral,

40

45

continuous release of a compound from a dosage form over a
prolonged period.
The phrase “pharmaceutically acceptable' is art-recog
nized. In certain embodiments, the term includes composi
tions, polymers and other materials and/or dosage forms
which are, within the scope of sound medical judgment, Suit
able for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic
response, or other problem or complication, commensurate
with a reasonable benefit/risk ratio.

50

55

60
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The phrase “pharmaceutically acceptable carrier' is art
recognized, and includes, for example, pharmaceutically
acceptable materials, compositions or vehicles, such as a
liquid or Solid filler, diluent, excipient, solvent or encapsulat
ing material, involved in carrying or transporting any subject
composition from one organ, or portion of the body, to
another organ, or portion of the body. Each carrier must be
“acceptable in the sense of being compatible with the other
ingredients of a Subject composition and not injurious to the
patient. In certain embodiments, a pharmaceutically accept
able carrier is non-pyrogenic. Some examples of materials
which may serve as pharmaceutically acceptable carriers
include: (1) Sugars, such as lactose, glucose and Sucrose; (2)
starches, such as corn starch and potato starch; (3) cellulose,
and its derivatives, such as Sodium carboxymethyl cellulose,
ethyl cellulose and cellulose acetate; (4) powdered traga
canth; (5) malt, (6) gelatin; (7) talc.; (8) excipients, such as
cocoa butter and Suppository waxes; (9) oils, such as peanut
oil, cottonseed oil, Sunflower oil, sesame oil, olive oil, corn oil

and Soybean oil, (10) glycols, such as propylene glycol; (11)
polyols. Such as glycerin, Sorbitol, mannitol and polyethylene

US 8,969,556 B2
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boxyl functional groups, N-acyl derivatives (e.g., N-acetyl)

7
glycol, (12) esters, such as ethyl oleate and ethyl laurate; (13)
agar, (14) buffering agents, such as magnesium hydroxide
and aluminum hydroxide; (15) alginic acid, (16) pyrogen
free water; (17) isotonic saline; (18) Ringer's solution; (19)
ethyl alcohol; (20) phosphate buffer solutions; and (21) other
non-toxic compatible Substances employed in pharmaceuti

N-Mannich bases, Schiffbases and enamines of amino func

cal formulations.

The compounds of the application are capable of further
forming salts. All of these forms are also contemplated within
the scope of the claimed invention.
"Pharmaceutically acceptable salt” of a compound means a
salt that is pharmaceutically acceptable and that possesses the
desired pharmacological activity of the parent compound.
For example, the salt can be an acid addition salt. One
embodiment of an acid addition salt is a hydrochloride salt
The pharmaceutically acceptable salts can be synthesized
from a parent compound that contains a basic oracidic moiety
by conventional chemical methods. Generally, such salts can
be prepared by reacting the free acid or base forms of these
compounds with a stoichiometric amount of the appropriate
base or acid in water or in an organic solvent, or in a mixture
of the two: generally, non-aqueous media like ether, ethyl
acetate, ethanol, isopropanol, or acetonitrile are preferred.
Lists of salts are found in Remington's Pharmaceutical Sci
ences, 18th ed. (Mack Publishing Company, 1990). For
example, salts can include, but are not limited to, the hydro
chloride and acetate salts of the aliphatic amine-containing,
hydroxyl amine-containing, and imine-containing com
pounds of the present invention.
It should be understood that all references to pharmaceu
tically acceptable salts include solvent addition forms (sol
vates) or crystal forms (polymorphs) as defined herein, of the

10

15

acetone Solvates, etc.
25

30

onate, or other ester.

The compounds described herein can also be prepared as
prodrugs, for example pharmaceutically acceptable prodrugs.
The terms “pro-drug and “prodrug are used interchange
ably herein and refer to any compound, which releases an
active parent drug in vivo. Since prodrugs are known to
enhance numerous desirable qualities of pharmaceuticals
(e.g., solubility, bioavailability, manufacturing, etc.) the com
pounds of the present invention can be delivered in prodrug
form. Thus, the present invention is intended to cover pro
drugs of the presently claimed compounds, methods of deliv
ering the same and compositions containing the same. "Pro
drugs are intended to include any covalently bonded carriers
that release an active parent drug of the present invention in
Vivo when such prodrug is administered to a subject. Prodrugs
of the present invention are prepared by modifying functional
groups present in the compound in Such a way that the modi
fications are cleaved, eitherin routine manipulation or in Vivo,
to the parent compound. Prodrugs include compounds of the
present invention wherein a hydroxy, amino, Sulfhydryl, car
boxy, or carbonyl group is bonded to any group that may be
cleaved in vivo to form a free hydroxyl, free amino, free
sulftydryl, free carboxy or free carbonyl group, respectively.
Examples of prodrugs include, but are not limited to, esters
(e.g., acetate, dialkylaminoacetates, formates, phosphates,
Sulfates, and benzoate derivatives) and carbamates (e.g., N.Ndimethylaminocarbonyl) of hydroxy functional groups, ester
groups (e.g., ethyl esters, morpholinoethanol esters) of car

“Solvates' means solvent addition forms that contain
either Stoichiometric or non Stoichiometric amounts of Sol

vent. Some compounds have a tendency to trap a fixed molar
ratio of solvent molecules in the crystalline solid state, thus
forming a solvate. If the solvent is water the solvate formed is
a hydrate, when the solvent is alcohol, the solvate formed is an
alcoholate. Hydrates are formed by the combination of one or
more molecules of water with one of the substances in which

same salt.

The compounds described herein can also be prepared as
esters, for example pharmaceutically acceptable esters. For
example, a carboxylic acid function group in a compound can
be converted to its corresponding ester, e.g., a methyl, ethyl,
or other ester. Also, an alcohol group in a compound can be
converted to its corresponding ester, e.g., an acetate, propi

tional groups, oximes, acetals, ketals and enolesters of ketone
and aldehyde functional groups in compounds of Formula I,
and the like, See Bundegaard, H. “Design of Prodrugs' p1-92,
Elesevier, New York-Oxford (1985).
“Protecting group' refers to a grouping of atoms that when
attached to a reactive group in a molecule masks, reduces or
prevents that reactivity. Examples of protecting groups can be
found in Green and Wuts, Protective Groups in Organic
Chemistry, (Wiley, 2. Sup.nded. 1991); Harrison and Harrison
et al., Compendium of Synthetic Organic Methods, Vols. 1-8
(John Wiley and Sons, 1971-1996); and Kocienski, Protect
ing Groups, (Verlag, 3.sup.rd ed. 2003).
Representative hydroxy protecting groups include those
where the hydroxy group is either acylated or alkylated Such
as benzyl, and trityl ethers as well as alkyl ethers, tetrahydro
pyranyl ethers, trialkylsilyl ethers and allyl ethers.
Additionally, the salts of the compounds described herein,
can exist in either hydrated or unhydrated (the anhydrous)
form or as solvates with other solvent molecules. Nonlimiting
examples of hydrates include monohydrates, dihydrates, etc.
Nonlimiting examples of Solvates include ethanol Solvates,
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the water retains its molecular state as HO, such combination
being able to form one or more hydrate.
The compounds, salts and prodrugs described herein can
exist in several tautomeric forms, including the enol and
imine form, and the keto and enamine form and geometric
isomers and mixtures thereof. All Such tautomeric forms are

included within the scope of the present invention. Tautomers
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exist as mixtures of a tautomeric set in Solution. In solid form,

usually one tautomer predominates. Even though one tau
tomer may be described, the present application includes all
tautomers of the present compounds. A tautomer is one of two
or more structural isomers that exist in equilibrium and are
readily converted from one isomeric form to another. This
reaction results in the formal migration of a hydrogen atom
accompanied by a Switch of adjacent conjugated double
bonds. In solutions where tautomerization is possible, a
chemical equilibrium of the tautomers will be reached. The
exact ratio of the tautomers depends on several factors,
including temperature, solvent, and pH. The concept of tau
tomers that are interconvertable by tautomerizations is called
tautomerism.
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Of the various types of tautomerism that are possible, two
are commonly observed. In keto-enol tautomerism a simul
taneous shift of electrons and a hydrogen atom occurs.
Tautomerizations can be catalyzed by: Base: 1. deprotona
tion; 2. formation of a delocalized anion (e.g., an enolate); 3.
protonation at a different position of the anion, Acid: 1. pro
tonation; 2. formation of a delocalized cation; 3. deprotona
tion at a different position adjacent to the cation.
As used herein, the term “analog refers to a chemical
compound that is structurally similar to another but differs
slightly in composition (as in the replacement of one atom by
an atom of a different element or in the presence of a particu
lar functional group, or the replacement of one functional
group by another functional group). Thus, an analog is a

US 8,969,556 B2
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compound that is similar or comparable in function and
appearance, but not in structure or origin to the reference
compound.
A“patient,” “subject” or “host to be treated by the subject
method may mean either a human or non-human animal. Such
as primates, mammals, and vertebrates.
The term “prophylactic or therapeutic' treatment is art
recognized and includes administration to the host of one or
more of the Subject compositions. If it is administered prior to
clinical manifestation of the unwanted condition (e.g., dis
ease or other unwanted state of the host animal) then the
treatment is prophylactic, i.e., it protects the host against
developing the unwanted condition, whereas if it is adminis
tered after manifestation of the unwanted condition, the treat

ment is therapeutic (i.e., it is intended to diminish, ameliorate,
or stabilize the existing unwanted condition or side effects
thereof).
The terms “therapeutic agent”, “drug”, “medicament” and
“bioactive Substance' are art-recognized and include mol
ecules and other agents that are biologically, physiologically,
or pharmacologically active Substances that act locally or
systemically in a patient or subject to treat a disease or con
dition. The terms include without limitation pharmaceuti
cally acceptable salts thereof and prodrugs. Such agents may
be acidic, basic, or salts; they may be neutral molecules, polar
molecules, or molecular complexes capable of hydrogen
bonding; they may be prodrugs in the form of ethers, esters,
amides and the like that are biologically activated when
administered into a patient or Subject.
The phrase “therapeutically effective amount' is an art
recognized term. In certain embodiments, the term refers to
an amount of a therapeutic agent that, when incorporated into
a polymer, produces some desired effect at a reasonable ben
efit/risk ratio applicable to any medical treatment. In certain
embodiments, the term refers to that amount necessary or
Sufficient to eliminate, reduce or maintain a target of a par
ticular therapeutic regimen. The effective amount may vary
depending on Such factors as the disease or condition being
treated, the particular targeted constructs being administered,
the size of the subject or the severity of the disease or condi
tion. One of ordinary skill in the art may empirically deter
mine the effective amount of a particular compound without
necessitating undue experimentation. In certain embodi
ments, a therapeutically effective amount of a therapeutic
agent for in vivo use will likely depend on a number of factors,
including: the rate of release of an agent from a polymer
matrix, which will depend in part on the chemical and physi
cal characteristics of the polymer; the identity of the agent;
the mode and method of administration; and any other mate
rials incorporated in the polymer matrix in addition to the

10
replaced. Ring double bonds, as used herein, are double
bonds that are formed between two adjacent ring atoms (e.g.,
C-C, C—N, O N—N).

5
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carbon include C-13 and C-14.
When a bond to a substituent is shown to cross a bond

connecting two atoms in a ring, then Such substituent can be
bonded to any atom in the ring. When a substituent is listed
without indicating the atom via which Such Substituent is
bonded to the rest of the compound of a given formula, then
Such substituent can be bonded via any atom in Such substitu
ent. Combinations of substituents and/or variables are per
missible, but only if such combinations result in stable com
pounds.
When an atom or a chemical moiety is preceded or fol
lowed by a subscripted numeric range (e.g., C.), the inven
tion is meant to encompass each number within the range as
well as all intermediate ranges. For example, “C. alkyl or
is meant to include alkyl groups with 1, 2, 3, 4, 5, 6, 1-6, 1-5,
1-4, 1-3, 1-2, 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5, and 5-6
carbons.
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agent.

The term "ED50 is art-recognized. In certain embodi
ments, ED50 means the dose of a drug, which produces 50%
of its maximum response or effect, or alternatively, the dose,
which produces a pre-determined response in 50% of test
subjects or preparations. The term “LD50 is art-recognized.
In certain embodiments, LD50 means the dose of a drug,
which is lethal in 50% of test subjects. The term “therapeutic
index' is an art-recognized term, which refers to the thera
peutic index of a drug, defined as LD50/ED50.
The term “substituted as used herein, means that any one
or more hydrogens on the designated atom is replaced with a
selection from the indicated group, provided that the desig
nated atoms normal valency is not exceeded, and that the
substitution results in a stable compound. When the substitu
ent is keto (i.e., =O), then 2 hydrogens on the atom are

With respect to any chemical compounds, the present
application is intended to include all isotopes of atoms occur
ring in the present compounds. Isotopes include those atoms
having the same atomic number but different mass numbers.
By way of general example and without limitation, isotopes
of hydrogen include tritium and deuterium, and isotopes of
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As used herein, “alkyl is intended to include both
branched (e.g., isopropyl, tert-butyl, isobutyl), straight-chain
e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl,
nonyl, decyl), and cycloalkyl (e.g., alicyclic) groups (e.g.,
cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooc
tyl), alkyl substituted cycloalkyl groups, and cycloalkyl sub
stituted alkyl groups. Such aliphatic hydrocarbon groups
have a specified number of carbon atoms. For example, C.
alkyl is intended to include C, C, C, C, Cs, and C alkyl
groups. As used herein, “lower alkyl refers to alkyl groups
having from 1 to 6 carbonatoms in the backbone of the carbon
chain. “Alkyl further includes alkyl groups that have oxygen,
nitrogen, Sulfur orphosphorous atoms replacing one or more
hydrocarbon backbone carbon atoms. In certain embodi
ments, a straight chain or branched chain alkyl has six or
fewer carbon atoms in its backbone (e.g., C-C for straight
chain, C-C for branched chain), for example four or fewer.
Likewise, certain cycloalkyls have from three to eight carbon
atoms in their ring structure. Such as five or six carbons in the
ring structure.
The term “substituted alkyls' refers to alkyl moieties hav
ing Substituents replacing a hydrogen on one or more carbons
of the hydrocarbon backbone. Such substituents can include,
for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alky
lcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxy
carbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl,
alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl,
dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phos
phate, phosphonato, phosphinato, cyano, amino (including
alkylamino, dialkylamino, arylamino, diarylamino, and alky
larylamino), acylamino (including alkylcarbonylamino, aryl
carbonylamino, carbamoylandureido), amidino, imino, Sulf
hydryl, alkylthio, arylthio, thiocarboxylate, sulfates,
alkylsulfinyl, Sulfonato, Sulfamoyl, Sulfonamido, nitro, trif
luoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aro
matic or heteroaromatic moiety. Cycloalkyls can be further
substituted, e.g., with the substituents described above. An
“alkylaryl' or an “aralkyl moiety is an alkyl substituted with
an aryl (e.g., phenylmethyl (benzyl)).
As used herein, “alkenyl is intended to include hydrocar
bon chains of either straight or branched configuration having
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one or more carbon-carbon double bonds occurring at any
stable point along the chain. For example, C. alkenyl is
intended to include C, C, C, Cs, and Coalkenyl groups.
Examples of alkenyl include, but are not limited to, ethenyl
and propenyl.
As used herein, “alkynyl' is intended to include hydrocar
bon chains of either straight or branched configuration having
one or more carbon-carbon triple bonds occurring at any
stable point along the chain. For example, C alkynyl is
intended to include C, C, C, Cs, and C alkynyl groups.
Examples of alkynyl include, but are not limited to, ethynyl
and propynyl.
Furthermore, “alkyl”, “alkenyl', and “alkynyl are
intended to include moieties which are diradicals, i.e., having
two points of attachment. A nonlimiting example of Such an
alkyl moiety that is a diradical is —CH2CH2—, i.e., a Calkyl
group that is covalently bonded via each terminal carbon

10

be substituted at one or more constituent atoms with, for

15

atom to the remainder of the molecule.

Aryl includes groups with aromaticity, including 5- and
6-membered “unconjugated, or single-ring, aromatic groups
that may include from Zero to four heteroatoms, as well as
"conjugated, or multicyclic, systems with at least one aro
matic ring. Examples of aryl groups include benzene, Substi
tuted phenyl, pyrrole, furan, thiophene, thiazole, isothiazole,
imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole,
pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
Furthermore, the term “aryl' includes multicyclic aryl
groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoX

example, a lower alkyl, a lower alkenyl, a lower alkoxy, a
lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a
nitro, a hydroxyl, —CF, or—CN, or the like.
As used herein, “halo' or “halogen refers to fluoro,
chloro, bromo, and iodo. “Counterion' is used to represent a
Small, negatively charged species such as fluoride, chloride,
bromide, iodide, hydroxide, acetate, and Sulfate.
"Stable compound' and “stable structure' are meant to
indicate a compound that is sufficiently robust to survive
isolation, and as appropriate, purification from a reaction
mixture, and formulation into an efficacious therapeutic
agent.

25

“Free compound is used herein to describe a compound in
the unbound state.
“Extinction coefficient' is a constant used in the Beer
Lambert Law which relates the concentration of the sub

azole, benzodioxazole, benzothiazole, benzoimidazole, ben

Zothiophene, methylenedioxyphenyl, quinoline, isoquino
line, napthridine, indole, benzofuran, purine, benzofuran,
deazapurine, or indolizine. Those aryl groups having heteroa
toms in the ring structure may also be referred to as “aryl
heterocycles”, “heterocycles,” “heteroaryls' or "heteroaro
matics’. The aromatic ring can be substituted at one or more
ring positions with Such substituents as described above, as
for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy,
arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy,
carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylami
nocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcar
bonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl,
aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato,
phosphinato, cyano, amino (including alkylamino, dialky
lamino, arylamino, diarylamino, and alkylaryl amino), acy
lamino (including alkylcarbonylamino, arylcarbonylamino,
carbamoylandureido), amidino, imino, Sulfhydryl, alkylthio.
arylthio, thiocarboxylate, Sulfates, alkylsulfinyl, Sulfonato,
Sulfamoyl, Sulfonamido, nitro, trifluoromethyl, cyano, azido,
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic
moiety. Aryl groups can also be fused or bridged with alicy
clic or heterocyclic rings, which are not aromatic So as to form
a multicyclic system (e.g., tetralin, methylenedioxyphenyl).
The terms "heterocyclyl or "heterocyclic group' include
closed ring structures, e.g., 3- to 10-, or 4- to 7-membered
rings, which include one or more heteroatoms. “Heteroatom’
includes atoms of any element other than carbon or hydrogen.
Examples of heteroatoms include nitrogen, oxygen, Sulfur
and phosphorus.
Heterocyclyl groups can be saturated or unsaturated and
include pyrrolidine, oxolane, thiolane, piperidine, piperazine,
morpholine, lactones, lactams such as azetidinones and pyr
rolidinones, Sultams, and Sultones. Heterocyclic groups such
as pyrrole and furan can have aromatic character. They
include fused ring structures such as quinoline and isoquino
line. Other examples of heterocyclic groups include pyridine
and purine. The heterocyclic ring can be substituted at one or
more positions with Such Substituents as described above, as

12
for example, halogen, hydroxyl, alkylcarbonyloxy, arylcar
bonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, car
boxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl,
alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phos
phinato, cyano, amino (including alkylamino, dialkylamino,
arylamino, diarylamino, and alkylarylamino), acylamino (in
cluding alkylcarbonylamino, arylcarbonylamino, carbamoyl
and ureido), amidino, imino, Sulfhydryl, alkylthio, arylthio.
thiocarboxylate, Sulfates, Sulfonato, Sulfamoyl, Sulfonamido,
nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aro
matic or heteroaromatic moiety. Heterocyclic groups can also
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stance being measured (in moles) to the absorbance of the
substance in solution (how well the substance in solution
blocks light beamed through it from getting out on the other
side). It is an indicator of how much light a compound absorbs
at a particular wavelength.
In the specification, the singular forms also include the
plural, unless the context clearly dictates otherwise. Unless
defined otherwise, all technical and scientific terms used
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herein have the same meaning as commonly understood by
one of ordinary skill in the art to which this invention belongs.
In the case of conflict, the present specification will control.
Throughout the description, where compositions are
described as having, including, or comprising, specific com
ponents, it is contemplated that compositions also consist
essentially of or consist of the recited components. Simi
larly, where methods or processes are described as having,
including, or comprising specific process steps, the processes
also consistessentially of, or consist of the recited processing
steps. Further, it should be understood that the order of steps
or order for performing certain actions is immaterial so long
as the invention remains operable. Moreover, two or more
steps or actions can be conducted simultaneously.
“Small molecule' is an art-recognized term. In certain
embodiments, this term refers to a molecule, which has a

molecular weight of less than about 2000 amu, or less than
about 1000 amu, and even less than about 500 amu.
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All percentages and ratios used herein, unless otherwise
indicated, are by weight.
This application relates, at least in part, to purine-based
triazoles, and particularly to hydrophobic, Substituted purine
based triazoles that can selectively inhibit certain protein
kinases, such as cyclin-dependent kinases (CDKs) (e.g.,
CDK5), and thereby suppress the cell cycle to promote cyto
protective effects. As discussed in more detail below, certain
diseases or disorders are mediated by overactivation of
CDKs, which can result in dysregulation of the cell cycle. The
hydrophobic, substituted purine-based triazoles of the appli
cation can inhibit or Suspend the cell cycle machinery and,
consequently, may be useful in modulating (e.g., Suspending)
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cell cycle progression to control cell growth and differentia
tion. In certain aspects, the hydrophobic, Substituted purine
based triazoles can effectively suppress neuronal toxicity
induced by amyloid B (AB)-oligomers.
In an aspect of the application the hydrophobic, Substituted
purine-based triazole (or analog thereof) can target, decrease,
or inhibit one or more CDKs that play a role in the regulation
of the mammalian cell cycle. CDKs that can be inhibited by
the application can include CDK1, CDK2, CDK3, CDK4.
CDK5, CDK6, CDK7, CDK8 and CDK9. In one example of
the application, the hydrophobic, substituted purine-based
triazole (or analog thereof) can inhibit CDK5. It will be
appreciated that the hydrophobic, substituted purine-based
triazole (or analog thereof) can inhibit other protein kinases,
such as AHR, GSK3beta, ERK, protein kinase C, her2, raf1.
MEK1, MAP kinase, EGF receptor, PDGF receptor, IGF
receptor, PI3 kinase, weel kinase, Src, and Abl as well as G
proteins and polymerases.
In one embodiment of the application, the hydrophobic,
Substituted purine-based triazole (or analog thereof) can have
the following general formula (I)
(I)

R3

5

10

15

25

/ NN

Y-S-C

SN

R2

or a pharmaceutically acceptable salt thereof,
where R is a hydrophobic, substituted or unsubstituted,
aryl, cyclic, or heterocyclic group; and
where R and R independently represent Substituents
Selected from the group consisting of hydrogen, halo
gen, C1-C4 alkyl, C-C alkenyl, C2-C2a alkynyl,
Cs-Co aryl, C-C2a alkaryl, C-C2a aralkyl, silyl,
hydroxyl, sulfhydryl, C-C alkoxy, C-C alkeny
loxy, C2-C2-alkynyloxy, Cs-Co aryloxy, acyl, C2-C24
alkylcarbonyl (-CO-alkyl), C-C arylcarbonyl
(—CO-aryl)), acyloxy (-O-acyl), C-C alkoxycarbo
nyl (—(CO)—O-alkyl). Co-Co aryloxycarbonyl
(—(CO)—O-aryl), C-C alkylcarbonato (-O(CO)—O-alkyl). Co-Co arylcarbonato (-O-(CO)—
O-aryl), carboxy ( COOH), carboxylato ( COO),
carbamoyl (-(CO)—NH), mono-(C-C alkyl)-Sub
stituted carbamoyl (—(CO) NH(C-C alkyl)), di
(C-C alkyl)-substituted carbamoyl (—(CO)—N(CC
alkyl)), mono-Substituted arylcarbamoyl
(—(CO). NH-aryl), thiocarbamoyl (—(CS) NH),
carbamido ( NH (CO) NH), cyano( CN), iso
cyano (NC), cyanato ( O CN), isocyanato (ONC),
isothiocyanato (—S NC), azido ( N=N*—N),
formyl (—(CO)—H), thioformyl ( (CS)—H), amino
(—NH), mono- and di-(C-C alkyl)-substituted
amino, mono- and di-(Cs-Co aryl)-substituted amino,
C-C alkylamido (-NH-(CO)-alkyl). Co-Co aryla
mido ( NH (CO)-aryl), imino, alkylimino,
arylimino, nitro ( NO), nitroso ( NO), sulfonic acid
(—SO -OH), Sulfonato (—SO-O.), C-C alkyl
Sulfanyl (-S-alkyl), arylsulfanyl, C-C alkylsulfinyl
(—(SO)-alkyl), Cs-Co arylsulfinyl (—(SO)-aryl),
C-C alkylsulfonyl ( -SO-alkyl), Cs-Co arylsulfo
nyl ( -SO-aryl), phosphono ( P(O)(OH)), phospho
nato ( P(O)(O—)), phosphinato ( -P(O)(O)), phos

furazan.

In other embodiments, R. and R can each independently
be a hydrogen, a halogen, C-C alkyl, C-C alkenyl,
C2-C2-alkynyl, Ca-Cao aryl, C-C2-alkaryl, C-C2a aralkyl,

N

R-S

14
pho ( PO), and phosphino ( -PH), and where each
R and R being independently unsubstituted or substi
tuted where appropriate by one or more —OH, halogen,
amino or alkyl groups.
In some embodiments, R can be a fluorinated aryl, cyclic,
or heterocyclic group. Such as a mono, di, or tri fluorinated
phenyl, cyopropane, cylcobutane, cyclohexane, pyrrole, pyri
dine, pyrimidine, pyrazole, triazole, furan, pyran, indazole, or

or an R. NH-, R.

NH-NH , NH

R NH

or

R. NH R NH radical, in which Ra represents a
straight- or branched-chain, Saturated or unsaturated alkyl
radical, an aryl orcycloalkyl radical or a heterocyclic ring and
R" represents a straight- or branched-chain, Saturated or
unsaturated alkylene group or an arylene or cycloalkylene
group, R and Reach containing 1 to 8 carbon atoms, and
where each R and R can independently be unsubstituted or
substituted, where appropriate, by one or more —OH, halo
gen, amino or alkyl groups.
In some embodiments, the hydrophobic, substituted
purine-based triazole or analog thereof can have the follow
ing formula (II):
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or a pharmaceutically acceptable salt thereof,
where X is a halogen;
where n is an integer from 0-5:
where n is an integer from 1-3:
where Y is substituted or unsubstituted C-C alkyl,
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24
alkaryl, C-C aralky; and C-C fluoroalkyl or C-C,
perfluoroalkyl.
where R2 is a hydrogen, a halogen, C1-C4 alkyl, C2-C24
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl,
C-C aralkyl, or an R. NH-, R. NH-NH-.
NH R NH or R. NH R NH- radical, in
which Ra represents a straight- or branched-chain, satu
rated or unsaturated alkyl radical, an aryl or cycloalkyl
radical or a heterocyclic ring and R' represents a straight
or branched-chain, Saturated or unsaturated alkylene
group or an arylene or cycloalkylene group, R and R'
each containing 1 to 8 carbon atoms, and where R is
unsubstituted or Substituted, where appropriate, by one
or more —OH, halogen, amino or alkyl groups. In one
example, R is hydrogen, Cl, F, an alkyl or Substituted
alkyl.
In some embodiments, the hydrophobic, substituted
purine-based triazole or analog thereof can have the follow
ing formula (III):
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In another embodiment of the application, the hydropho
bic, Substituted purine-based triazole or analog thereof can
have the following formula (V):

(III)

(V)
Y

Or )--().S-CN
x-

Y.

or a pharmaceutically acceptable salt thereof, wherein
where n is an integer from 0-5; and C-C fluoroalkyl or
C-C perfluoroalkyl
where R2 is a hydrogen, a halogen, C1-C4 alkyl, C-C24
alkenyl, C-C alkynyl, C-C aryl, C-C alkaryl,
C-C aralkyl, or an R. NH , R. NH-NH-,
NH R NH or R. NH R NH- radical, in
which R4 represents a straight- or branched-chain, Satu
rated or unsaturated alkyl radical, an aryl or cycloalkyl
radical or a heterocyclic ring and R' represents a straight
or branched-chain, Saturated or unsaturated alkylene
group or an arylene or cycloalkylene group, R and R'
each containing 1 to 8 carbon atoms, and where R is
unsubstituted or Substituted, where appropriate, by one
or more —OH, halogen, amino or alkyl groups. In one
example, R is hydrogen, Cl, F, an alkyl or Substituted
alkyl.
In another embodiment of the application, the hydropho
bic, Substituted purine-based triazole or analog thereof can
have the following formula (IV):
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(IV)

| N

N-4
/ N

x- )- S-C

or a pharmaceutically acceptable salt thereof,
where n is an integer from 1-3:
where Y is substituted or unsubstituted C-C alkyl,
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24
alkaryl, C-C2a aralky; and
where R is a hydrogen, a halogen, C-C alkyl, C-C,
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl,
C-C aralkyl, or an R. NH , R. NH-NH-,
NH R NH- or R. NH R NH- radical, in
which R4 represents a straight- or branched-chain, Satu
rated or unsaturated alkyl radical, an aryl or cycloalkyl
radical or a heterocyclic ring and R' represents a straight
or branched-chain, Saturated or unsaturated alkylene
group or an arylene or cycloalkylene group, R and R'
each containing 1 to 8 carbon atoms, and where R is
unsubstituted or Substituted, where appropriate, by one
or more —OH, halogen, amino or alkyl groups. In one
example, R is hydrogen, Cl, F, an alkyl or Substituted
alkyl.

NN

/ -Q

15

Y

N

2

story

2

N-4

N

10

40

R2

or a pharmaceutically acceptable salt thereof,
where n is an integer from 1-3; and C-C fluoroalkyl or
C-C perfluoroalkyl.
where Y is substituted or unsubstituted C-C alkyl,
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24
alkaryl, C-C2a aralky;
where R is a hydrogen, a halogen, C-C alkyl, C-C,
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl,
C-C aralkyl, or an R. NH , R. NH-NH-,
NH R NH- or R. NH R NH- radical, in
which R represents a straight- or branched-chain, Satu
rated or unsaturated alkyl radical, an aryl or cycloalkyl
radical or a heterocyclic ring and R' represents a straight
or branched-chain, Saturated or unsaturated alkylene
group or an arylene or cycloalkylene group, R and R'
each containing 1 to 8 carbon atoms, and where R is
unsubstituted or Substituted, where appropriate, by one
or more —OH, halogen, amino or alkyl groups. In one
example, R is hydrogen, Cl, F, an alkyl or Substituted
alkyl.
In yet another embodiment of the application, the hydro
phobic, substituted purine-based triazole or analog thereof
can have the following formula (VI):
Y

N

45

50

55

60

65

(VI)

N-4

(-\, CyKys,
N

R

or a pharmaceutically acceptable salt thereof,
where n is an integer from 1-3:
where Y is substituted or unsubstituted C-C alkyl,
C-C alkenyl, C-C alkynyl, C-Co aryl, C-C,
alkaryl, C-C aralky; and C-C fluoroalkyl or C-C
perfluoroalkyl.
where Ro and R are each independently a hydrogen or a
halogen; and
where R is a halogen atom, C-C alkyl, C-C alkenyl,
C2-C2a alkynyl, Cs-Co aryl, C-C2a alkaryl, C-C24
aralkyl, or an R. NH , R. NH NH , NH,
R" NH or R. NH R NH radical, in which
R represents a straight- or branched-chain, Saturated or
unsaturated alkyl radical, an aryl or cycloalkyl radical or
a heterocyclic ring and R' represents a straight- or

US 8,969,556 B2
17
branched-chain, Saturated or unsaturated alkylene group
or an arylene or cycloalkylene group, Ra and R' each
containing 1 to 8 carbon atoms, and where R is unsub
stituted or substituted, where appropriate, by one or
more —OH, halogen, amino or alkyl groups. In one
example, R is hydrogen, Cl, F, an alkyl or Substituted
alkyl.
In another embodiment of the application, the hydropho
bic, Substituted purine-based triazole or analog thereof can
have the following formula (VII):

18
the hydrogen bonding interactions with the fluorines at the
enzyme active site. Additionally, the halogen-substituted aryl
moiety or moieties that form part of the substituted purine
based triazoles impart the substituted purine-based triazoles
with sufficient hydrophobicity to facilitate entry of the sub
stituted purine-based triazoles into and across cell mem
branes.
10

(VII)
Y

N

15

N-4

XS-N, y- / -Q
N
Qor a pharmaceutically acceptable salt thereof,
where R is hydrogen or a halogen;
where R is O, N or S;
where n is an integer from 1-3:
where Y is substituted or unsubstituted C-C alkyl,
C2-C2a alkenyl, C2-C2a alkynyl, Ca-Co aryl, C-C24
alkaryl, C-C aralky; and C-C fluoroalkyl or C-C,
perfluoroalkyl.
where R is a halogenatom, C-C alkyl, C-C alkenyl,
C-C alkynyl, C-Co aryl, C-C alkaryl, C-C,
aralkyl, or an R. NH , R. NH NH NH
R" NH- or R. NH R NH- radical, in which
R represents a straight- or branched-chain, Saturated or
unsaturated alkyl radical, an aryl or cycloalkyl radical or
a heterocyclic ring and R' represents a straight- or
branched-chain, Saturated or unsaturated alkylene group
or an arylene or cycloalkylene group, Ra and R' each
containing 1 to 8 carbon atoms, and where R is unsub
stituted or substituted, where appropriate, by one or
more —OH, halogen, amino or alkyl groups. In one
example, R is hydrogen, Cl, F, an alkyl or Substituted
alkyl.
In still other embodiments, the substituted purine-based
triazoles can be selected from compounds III-VII, where n is
an integer from 0-5, where R is a hydrogen, a halogen (e.g.,
Cl or F), an alkyl or substituted alkyl; where R. R. Rare
each independently a hydrogen or a halogen; and where R.
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49:31-33, 2010; and Tron, G C et al., Med. Res. Rev. 28:278

308, 2008). For instance, click chemistry can be used to
couple one or more hydrophobic, halogen-substituted aryl
moieties to a purine-derived alkyne through 1,2,3-triazole
linkage(s). Introduction of a fluorinated aryl group, for
example, can improve the therapeutic efficiency of the Sub
stituted purine-based triazoles of the application as a result of

(

3

It will be readily appreciated by those of skill in the art that
depending on the Substituents, the purine analogs of the
present invention can be a racemic mixture or either of a pair
The hydrophobic, substituted purine-based triazoles (or
analogs thereof) can be synthesized using click chemistry.
Click chemistry is a convenient way for tethering halogenated
and variously substituted aryl moieties to purine-derived
alkynes (see, e.g., Spiteri, C. et al., Angew. Chem. Int. Ed.

Scheme 1. Synthesis of purine-based fluoroaryl triazoles:

40

is O, N or S.

of diastereomers or enantiomers.

In one example of the application, a triazole and its fluori
nated derivatives can be prepared by a Cu(I)-catalyzed 1,3dipolar cycloaddition reaction of the corresponding alkyne
and azide substrates. As shown below in Scheme 1, synthesis
can begin with the reaction of 2,6-dichloropurine (Compound
3) with benzylamine () as described, for example, by
Oumata, N. et al., Org. Process Res. Dev. 13:641-644 (2009).
Using the conditions set forth in the Example below, the
reaction can be completed in about 15 minutes at about 60°C.
2-chloro-6-benzylaminopurine (Compound 4) can be prop
argylated using propargyl bromide in DMSO under mild con
ditions to yield 2-chloro-6-benzylamino-9-(2-propynyl)
purine (Compound 5). The Cu(I)-catalyzed azide-alyne click
reaction (as described, for example, by Amblard, F. et al.,
Chem. Rev. 109:4207-4220, 2009) of 2-chloro-6-benzy
lamino-9-(2-propynyl) purine (Compound 5) with fluori
nated benzyl azides (which can be prepared in situ from their
corresponding benzyl bromides) can then yield 1,4-disubsti
tuted triazoles or, more specifically, 2-chloro-6-benzy
lamino-9-1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl-methyl
purine (Compound 7), 2-chloro-6-benzylamino-9-1-(2,6difluorobenzyl)-1H-1,2,3-triazol-4-yl-methylpurine
(Compound 8), and 2-chloro-6-benzylamino-9-1-(pen
tafluorobenzyl)-1H-1,2,3-triazol-4-yl-methylpurine (Com
pound 9).
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reagents and conditions: benzylamine/EtsN/n-BuOH, 60°C/15 min, 95%; propargyl
bromide K2CO3DMSO, 0°C. 1 h, 80%; fluorophenylmethyl bromide (or
phenylmethyl bromide), sodium azide?Cu(I)BriEtNDMSO, RT/30 min, 80-89%.

The substituted purine-based triazoles described herein
can be incorporated into a variety of formulations for thera
peutic administration. More particularly, the substituted
purine-based triazoles can beformulated into pharmaceutical
compositions by combination with appropriate, pharmaceu
tically acceptable carriers or diluents, and may be formulated
into preparations in Solid, semi-solid, liquid orgaseous forms,
Such as tablets, capsules, pills, powders, granules, dragees,
gels, slurries, ointments, Solutions, Suppositories, injections,

25

inhalants and aerosols. As such, administration of the Substi

30

tuted purine-based triazoles can be achieved in various ways,
including oral, buccal, rectal, parenteral, intraperitoneal,
intradermal, transdermal, intracheal, etc., administration.

Moreover, the substituted purine-based triazoles can be
administered in a local rather than systemic manner, for
example via injection of the compound directly into a tissue
being treated, often in a depot or Sustained release formula

35

binders such as starches, and/or lubricants such as talc or

tion.

In addition, the substituted purine-based triazoles can be
administered in a targeted drug delivery system, for example,
in a liposome coated with tissue or cell-specific antibody.
Such liposomes will be targeted to and taken up selectively by

40

the tissue or cell.

Formulations for use in the application are found in Rem
ington's Phannaceutical Sciences (Mack Publishing Com
pany, Philadelphia, Pa., 17th ed. (1985)), which is incorpo
rated herein by reference. Moreover, for a brief review of
methods for drug delivery, see, Langer, Science 249:1527
1533 (1990), which is incorporated herein by reference. The
pharmaceutical compositions described herein can be manu

45

For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional man

50

For administration by inhalation, the compounds described
herein are conveniently delivered in the form of an aerosol
spray presentation from pressurized packs or a nebulizer, with
the use of a Suitable propellant, e.g., dichlorodifluo

.

romethane, trichlorofluoromethane, dichlorotetrafluoroet
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col; and if desired, with conventional additives Such as solu

bilizers, isotonic agents, Suspending agents, emulsifying
agents, stabilizers and preservatives. The Substituted purine
based triazoles may be formulated in aqueous solutions, such
as in physiologically compatible buffers such as Hanks’s
Solution, Ringer's Solution, orphysiological Saline buffer. For

magnesium Stearate and, optionally, stabilizers. In soft cap
Sules, the active compounds may be dissolved or Suspended in
Suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages
Suitable for Such administration.

factured in a manner that is known to those of skill in the art,

i.e., by means of conventional mixing, dissolving, granulat
ing, dragee-making, levigating, emulsifying, encapsulating,
entrapping or lyophilizing processes. The following methods
and excipients are merely exemplary and are in no way lim
iting.
For injection, the substituted purine-based triazoles can be
formulated into preparations by dissolving, Suspending or
emulsifying them in an aqueous or nonaqueous solvent. Such
as Vegetable or other similar oils, synthetic aliphatic acid
glycerides, esters of higher aliphatic acids or propylene gly

20
transmucosal administration, penetrants appropriate to the
barrier to be permeated are used in the formulation. Such
penetrants are generally known in the art.
For oral administration, the substituted purine-based tria
Zoles can be formulated by combining with pharmaceutically
acceptable carriers that are well known in the art. Such car
riers enable the compounds to be formulated as tablets, pills,
dragees, capsules, emulsions, lipophilic and hydrophilic Sus
pensions, liquids, gels, syrups, slurries, Suspensions and the
like, for oral ingestion by a patient to be treated. Pharmaceu
tical preparations for oral use can be obtained by mixing the
compounds with a solid excipient, optionally grinding a
resulting mixture, and processing the mixture of grammes,
after adding suitable auxiliaries, if desired, to obtaintablets or
dragee cores. Suitable excipients are, in particular, fillers such
as Sugars, including lactose, Sucrose, mannitol, or Sorbitol;
cellulose preparations such as, for example, maize starch,
wheat starch, rice starch, potato starch, gelatin, gum traga
canth, methyl cellulose, hydroxypropylmethyl-cellulose,
Sodium carboxymethylcellulose, and/or polyvinylpyrroli
done (PVP). If desired, disintegrating agents may be added,
Such as the cross-linked polyvinyl pyrrolidone, agar, or alg
inic acid or a salt thereof Such as Sodium alginate.
Dragee cores can be provided with Suitable coatings. For
this purpose, concentrated Sugar Solutions may be used,
which may optionally contain gum arabic, talc, polyvinyl
pyrrolidone, carbopol gel, polyethylene glycol, and/or tita
nium dioxide, lacquer Solutions, and Suitable organic solvents
or solvent mixtures. Dyestuffs or pigments may be added to
the tablets or dragee coatings for identification or to charac
terize different combinations of active compound doses.
Pharmaceutical preparations which can be used orally
include push-fit capsules made of gelatin, as well as Soft,
sealed capsules made of gelatin and a plasticizer, Such as
glycerol or Sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler Such as lactose,
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hane, carbon dioxide or other Suitable gas, or from propellant
free, dry-powder inhalers. In the case of a pressurized aerosol
the dosage unit may be determined by providing a valve to
deliver a metered amount. Capsules and cartridges of e.g.,
gelatin for use in an inhaler or insufflator may be formulated
containing a powder mix of the compound and a suitable
powder base. Such as lactose or starch.
The substituted purine-based triazoles may be formulated
for parenteral administration by injection, e.g., by bolus
injection or continuous infusion. Formulations for injection
may be presented in unit dosage form, e.g., in ampules or in
multidose containers, with an added preservative. The com
positions may take such forms as Suspensions, Solutions or
emulsions in oily or aqueous vehicles, and may contain for
mulatory agents such as Suspending, stabilizing and/or dis
persing agents.
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Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water
soluble form. Additionally, Suspensions of the active com
pounds may be prepared as appropriate oily injection Suspen
sions. Suitable lipophilic solvents or vehicles include fatty
oils such as sesame oil, or synthetic fatty acid esters. Such as
ethyl oleate or triglycerides, or liposomes. Aqueous injection
Suspensions may contain Substances which increase the vis
cosity of the Suspension, such as Sodium carboxymethyl cel
lulose, Sorbitol, or dextran. Optionally, the Suspension may
also contain stabilizers or agents, which increase the solubil
ity of the compounds to allow for the preparation of highly
concentrated Solutions. Alternatively, the Substituted purine
based triazoles may be in powderform for constitution with a
Suitable vehicle, e.g., sterile pyrogen-free water, before use.
The substituted purine-based triazoles may also be formu
lated in rectal compositions such as Suppositories or retention
enemas, e.g., containing conventional Suppository bases Such
as cocoa butter, carbowaxes, polyethylene glycols or other
glycerides, all of which melt at body temperature, yet are
solidified at room temperature.
In addition to the formulations described previously, the
substituted purine-based triazoles may also be formulated as
a depot preparation. Such long acting formulations may be
administered by implantation (for example Subcutaneously or
intramuscularly) or by intramuscular injection. Thus, for
example, the substituted purine-based triazoles may be for
mulated with suitable polymeric or hydrophobic materials
(for example as an emulsion in an acceptable oil) or ion
exchange resins, or as sparingly soluble derivatives, for
example, as a sparingly soluble salt.
Alternatively, other delivery systems for hydrophobic sub
stituted purine-based triazoles may be employed. Liposomes
and emulsions are well known examples of delivery vehicles
or carriers for hydrophobic drugs. Certain organic solvents
Such as dimethylsulfoxide also may be employed, although
usually at the cost of greater toxicity.
Additionally, the substituted purine-based triazoles may be
delivered using a Sustained-release system, such as semiper
meable matrices of Solid hydrophobic polymers containing
the therapeutic agent. Various types of Sustained-release
materials have been established and are well known by those
skilled in the art. Sustained-release capsules may, depending
on their chemical nature, release the compounds for a few
weeks up to over 100 days.
The pharmaceutical compositions also may comprise Suit
able Solid or gel phase carriers or excipients. Examples of
Such carriers or excipients include but are not limited to
calcium carbonate, calcium phosphate, various Sugars,
starches, cellulose derivatives, gelatin, and polymers such as
polyethylene glycols.
Pharmaceutical compositions can also include composi
tions wherein the substituted purine-based triazoles are con
tained in a therapeutically effective amount. The amount of
composition administered will, of course, be dependent on
the subject being treated, on the subjects weight, the severity
of the affliction, the manner of administration and the judg
ment of the prescribing physician. Determination of an effec
tive amount is well within the capability of those skilled in the
art, especially in light of the detailed disclosure provided
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culture), or the ICoo as determined in cell culture (i.e., the
concentration of compound that is lethal to 100% of a cell
culture). Such information can be used to more accurately
determine useful doses in humans. Initial dosages can also be
estimated from in vitro or in vivo data.

10

of a CDK inhibitor, such as Roscovitine. In this method, an
15

initial dosage can be obtained by multiplying the ratio of
effective concentrations obtained in cell culture assay for the
substituted purine-based triazoles described herein and a
known CDK inhibitor by the effective dosage of the known
CDK inhibitor. For example, if a substituted purine-based
triazole described herein is twice as effective in cell culture
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herein.

For any compound used in a method described herein, a
therapeutically effective dose can be estimated initially from
cell culture assays. For example, a dose can be formulated in
animal models to achieve a circulating concentration range
that includes the ICso as determined in cell culture (i.e., the
concentration of test compound that is lethal to 50% of a cell

Initial dosages can also be formulated by comparing the
effectiveness of the compounds described herein in cell cul
ture assays with the effectiveness of known drugs. For
instance, initial dosages can be formulated by comparing the
effectiveness of the substituted purine-based triazoles
described herein in cell culture assays with the effectiveness
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assay than Roscovitine, an initial effective dosage of the
substituted purine-based triazoles would be one-half the
known dosage for Roscovitine. Using these initial guidelines
one having ordinary skill in the art could determine an effec
tive dosage in humans.
Moreover, toxicity and therapeutic efficacy of the com
pounds described herein can be determined by standard phar
maceutical procedures in cell cultures or experimental ani
mals, e.g., by determining the LDs (the dose lethal to 50% of
the population) and the EDs (the dose therapeutically effec
tive in 50% of the population). The dose ratio between toxic
and therapeutic effect is the therapeutic index and can be
expressed as the ratio between LDs and EDso. Substituted
purine-based triazoles, which exhibit high therapeutic indices
are preferred. The data obtained from these cell culture assays
and animal studies can be used in formulating a dosage range
that is not toxic for use in human. The dosage of Such com
pounds lies preferably within a range of circulating concen
trations that include the EDs with little or no toxicity. The
dosage may vary within this range depending upon the dosage
form employed and the route of administration utilized. The
exact formulation, route of administration and dosage can be
chosen by the individual physician in view of the patients
condition. (See, e.g., Finglet al., 1975. In: The Pharmaco
logical Basis of Therapeutics, Ch. 1, p. 1).
Dosage amount and interval may be adjusted individually
to provide plasma levels of the active compound, which are
sufficient to maintain therapeutic effect. Usual patient dos
ages for oral administration range from about 50-2000
mg/kg/day, commonly from about 100-1000 mg/kg/day,
preferably from about 150-700 mg/kg/day and most prefer
ably from about 250-500 mg/kg/day. Preferably, therapeuti
cally effective serum levels will beachieved by administering
multiple doses each day. In cases of local administration or
selective uptake, the effective local concentration of the drug
may not be related to plasma concentration. One having skill
in the art will be able to optimize therapeutically effective
local dosages without undue experimentation.
The substituted purine-based triazoles described herein
can be used either in vitro or in vivo for a variety of purposes.
As discussed previously, in Some embodiments of the appli
cation, the Substituted purine-based triazoles can be used to
inhibit protein kinases, G proteins and polymerases. Protein
kinases which can be inhibited using the purine-based triaz
oles described herein include, but are not limited to, cyclin
dependent kinases (CDKs), MAP kinases (p38, ERK),
(MAPK/MEK/MEKK), cAMP-dependent kinase, c-GMP
dependent kinase, Calmodulin-dependent kinase, CSK
(C-src like kinase) pp 60 c-Src, myosin light chain kinase,
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JNK kinase, IKB kinase, Protein kinase C, etc. In a presently
preferred embodiment, the protein kinase is a CDK. Such
CDKs include CDK1 (or, interchangeably, CDC2) and
CDK2-CDK8. G proteins that can be inhibited using the
substituted purine-based triazoles include, but are not limited
to, GTP binding proteins. Polymerases, which can be inhib
ited using the purine analogs of the present invention include,
but are not limited to, DNA polymerase a, DNA polymerase
6, DNA topoisomerase I, topoisomerase II, phosphatases,
telomerases, etc. Other protein kinases, G proteins and poly
merases which can be inhibited using the substituted purine

10

based triazoles described herein will be known to those of
skill in the art.

In other embodiments, the substituted purine-based triaz
oles can be used in a method for inhibiting at least one CDK
in a subject. Due to the key role of CDKs in regulating the cell
cycle and cellular proliferation, the substituted purine-based
triazoles (or analogs thereof) disclosed herein may act as
reversible cytostatic agents, which may be useful in the treat
ment of any disease process featuring abnormal cell cycle or
cellular proliferation, including, but not limited to, abnormal
stimulation of endothelial cells (e.g., atherosclerosis), neo
plastic disorders, Solid tumors and tumor metastasis, benign
tumors, for example, hemangiomas, acoustic neuromas, neu
rofibromas, trachomas, and pyogenic granulomas, cancer,
vascular malfunctions, abnormal wound healing, inflamma
tory and immune disorders, Bechet's disease, gout or gouty
arthritis, abnormal angiogenesis accompanying, for example,
rheumatoid arthritis, psoriasis, alopecia, diabetic retinopathy,
other ocular angiogenic diseases, such as retinopathy of pre
maturity (retrolental fibroplastic), macular degeneration, cor
neal graft rejection, neuroscular glaucoma and Oster Webber
syndrome, fungal, parasitic and viral infections, such as
cytomegaloviral infections, neurological disorders, stroke,
neurofibromatosis, endotoxic shock, hypertrophic scar for
mation, inflammatory bowel disease, transplant rejection,
vascular Smooth muscle cell proliferation associated with
atherosclerosis, pulmonary fibrosis, arthritis, glomerulone
phritis, restenosis following angioplasty or vascular Surgery,
and other post-Surgical Stenosis and restenosis.
In one specific embodiment, the substituted purine-based
triazoles can be administered to a Subject to treat a prolifera
tive disorder of the subject. The proliferative disorder
described herein can include, for example cardiovascular dis
orders, such as restenosis and cardiomyopathy, neoplastic
disorders, auto-immune disorders, such as glomerulonephri
tis and rheumatoid arthritis, dermatological disorders such as
psoriasis, anti-inflammatory, anti-fungal, antiparasitic disor
ders, such as malaria, emphysema and alopecia. In these
disorders, the substituted purine-based triazoles described
herein may induce apoptosis or maintain stasis within the
desired cells as required.
The substituted purine-based triazoles described herein
can inhibit any of the steps or stages in the cell cycle, for
example, formation of the nuclear envelope, exit from the
quiescent phase of the cell cycle (GO), G1 progression, chro
mosome decondensation, nuclear envelope breakdown,
START, initiation of DNA replication, progression of DNA
replication, termination of DNA replication, centroSome
duplication, G2 progression, activation of mitotic or meiotic
functions, chromosome condensation, centrosome separa
tion, microtubule nucleation, spindle formation and function,
interactions with microtubule motor proteins, chromatid
separation and segregation, inactivation of mitotic functions,
formation of contractile ring, and cytokinesis functions. In
particular, the Substituted purine-based triazoles may influ
ence certain gene functions such as chromatin binding, for
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mation of replication complexes, replication licensing, phos
phorylation or other secondary modification activity,
proteolytic degradation, microtubule binding, actin binding,
septin binding, microtubule organising centre nucleation
activity and binding to components of cell cycle signalling
pathways.
In one embodiment, the proliferative disorder can be a
neoplastic disorder. By way of example, neoplastic disorders
treatable by the compounds described herein can include, but
are not limited to: carcinoma, including that of the bladder,
breast, colon, kidney, liver, lung, including Small cell lung
cancer, esophagus, gall bladder, ovary, pancreas, stomach,
cervix, thyroid, prostate, and skin, including squamous cell
carcinoma; hematopoietic tumors of lymphoid lineage,
including leukemia, acute lymphocytic leukemia, acute lym
phoblastic leukemia, B-cell lymphoma, T-cell lymphoma,
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, hairy cell
lymphoma, and Burkett's lymphoma; hematopoietic tumors
of myeloid lineage, including acute and chronic myelogenous
leukemias, myelodysplastic syndrome, and promyelocytic
leukemia; tumors of mesenchymal origin, including fibrosa
rcoma and rhabdomyosarcoma; tumors of the central and
peripheral nervous system, including astrocytoma, neuro
blastoma, glioma, and Schwannomas; and other tumors,
including melanoma, seminoma, teratocarcinoma, osteosar
coma, Xenoderoma pigmentosum, keratoctanthoma, thyroid
follicular cancer, and Kaposi's sarcoma.
Neoplastic disorders, such as cancer are typically charac
terized by abnormal cell division as a result of dysfunctional
signaling cascades and/or checkpoint control within the cell
cycle. For example, the first stage of the cell cycle, which is
mediated by a highly controlled kinase family, consists of a
cascade of protein phosphorylations that relay a cell from one
stage to the next. The second stage is a set of checkpoints that
monitor completion of critical events and delay progression
to the next stage, if necessary. CDKs are critically important
in the first stage, and their overactivity can result in disruption
of the cell cycle and progression to uncontrolled cell growth.
By inhibiting at least one CDK in the subject, the cell cycle in
neoplastic or potentially neoplastic cells can be maintained or
suspended so that the cells do not become hyperproliferative.
In another embodiment, the substituted purine-based tria
Zoles can be administered to a subject to treat a neurological
or neurodegenerative disorder including central nervous sys
tem disorders or peripheral nervous system disorders.
Examples of neurological disorders treated by the com
pounds and compositions described herein can include, but
are not limited to, Alzheimer's disease, Parkinson's disease,
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Huntington's disease, amyotrophic lateral Sclerosis, multiple
sclerosis, elderly dementia, Tay-Sachs disease, Sandhoffs
disease, Hurler's syndrome, Krabbe's disease, central or
peripheral nervous system injury, epilepsy, multiple Sclerosis,
central or peripheral nervous system trauma, stroke, Asperger
syndrome, Autism, Attention deficit hyperactivity disorder
(ADHD), Cerebral palsy, Dyslexia, seizures, Mild Cognitive
Impairment (MCI), retinitis pigmentosa, spinal muscular
atrophy, motor neuron disease, bipolar disorder, cerebellar
degeneration or age associated memory impairment.
In one example, the Substituted purine-based triazoles
described herein can be used to treat a subject suffering from
a neurological disorder mediated by AB, Such as Alzheimer's
disease. The Substituted purine-based triazoles can be can
administered at a therapeutically effective amount in a phar
maceutical composition that includes the purine-based triaz
ole and a pharmaceutical carrier. The therapeutically effective
amount of the pharmaceutical composition can be adminis
tered to the Subject via an appropriate route. Upon adminis
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tration to the subject, the substituted purine-based triazole can
readily traverse neuronal cell membranes as a result of the
compounds hydrophobic nature. The substituted purine
based triazole can then selectively inhibit CDK5 due to the
hydrogen bonding interactions at the enzyme’s active site
Inhibition of CDK5 can consequently prevent or mitigate
tau-hyperphosphorylation, increase levels of synaptic mark
ers, and Suppress or Suspend the neuronal cell cycle to pro
mote neuronal Survival.

In another embodiment, the substituted purine-based tria
Zoles can be used as an antiviral agent. For example, the
substituted purine-based triazoles described herein can be
used in the preparation of a medicament for treating a viral
disorder, such as human cytomegalovirus (HCMV), herpes
simplex virus type 1 (HSV-1), human immunodeficiency
virus type 1 (HIV-1), and varicella Zoster virus (VZV).
In a more preferred embodiment, the substituted purine

10

15

based triazoles can be administered at an amount effective to
inhibit one or more of the host cell CDKs involved in viral

replication (Wang D, De la Fuente C, Deng L, Wang L,
Zilberman I, Eadie C, Healey M, Stein D, Denny T. Harrison
L E. Meijer L. Kashanchi F Inhibition of human immunode
ficiency virus type 1 transcription by chemical cyclin-depen
dent kinase inhibitors. J. Virol. 2001: 75: 7266-7279). As
defined herein, an anti-viral effect within the scope of the
present invention may be demonstrated by the ability to
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inhibit at least one CDK.

amount sufficient to inhibit GSK3.

In a particular embodiment, the substituted purine-based
triazoles can be used in the treatment of a viral disorder which

is CDK dependent or sensitive. CDK dependent disorders are
associated with an above normal level of activity of one or
more CDK enzymes. Such disorders can be associated with
an abnormal level of activity of CDK. A CDKsensitive dis
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metabolic aberration. In such scenarios, CDK can be said to

be part of the sensitive metabolic pathway and CDK inhibi
tors may therefore be active in treating Such disorders.
Another aspect of the invention relates to the use of the
Substituted purine-based triazoles, or pharmaceutically
acceptable salts thereof, in the preparation of a medicament
for treating diabetes. In a particular embodiment, the diabetes
is type II diabetes.
GSK3 is one of several protein kinases that phosphorylate
glycogen synthase (GS). The stimulation of glycogen synthe
sis by insulin in skeletal muscle results from the dephospho
rylation and activation of G.S. GSK3's action on GS thus
results in the latter's deactivation and thus suppression of the
conversion of glucose into glycogen in muscles.
Type II diabetes (non-insulin dependent diabetes mellitus)
is a multi-factorial disease. Hyperglycaemia is due to insulin
resistance in the liver, muscles, and other tissues, coupled
with impaired secretion of insulin. Skeletal muscle is the
main site for insulin-stimulated glucose uptake, there it is
either removed from circulation or converted to glycogen.
Muscle glycogen deposition is the main determinant in glu
cose homeostasis and type II diabetics have defective muscle
glycogen storage. There is evidence that an increase in GSK3
activity is important in type II diabetes Chen, Y. H.; Hansen,
L.; Chen, M. X., Bjorbaek, C.; Vestergaard, H.; Hansen, T.;
Cohen, P.T.: Pedersen, O. Diabetes, 1994, 43, 1234. Further
more, it has been demonstrated that GSK3 is over-expressed
in muscle cells of type II diabetics and that an inverse corre
lation exists between skeletal muscle GSK3 activity and insu
lin action Nikoulina, S. E.; Ciaraldi, T. P.; Mudaliar, S.;
Mohideen, P.; Carter, L.; Henry, R. R. Diabetes, 2000, 49,
263). GSK3 inhibition using the substituted purine based

The following example is for the purpose of illustration
only and is not intended to limit the scope of the claims, which
are appended hereto.
EXAMPLE

order is a disorder in which an aberration in the CDKlevel is

not the primary cause, but is downstream of the primary
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triazoles described herein is therefore of therapeutic signifi
cance in the treatment of diabetes, particularly type II, and
diabetic neuropathy.
Yet another embodiment of the application relates to the
use of the substituted purine-based triazoles in the prepara
tion of a medicament for treating alopecia. Hair growth is
controlled by the Wnt signalling pathway, in particular Wnt
3. In tissue-culture model systems of the skin, the expression
of non-degradable mutants of B-catenin leads to a dramatic
increase in the population of putative stem cells, which have
greater proliferative potential Zhu, A. J.; Watt, F. M. Devel
opment, 1999, 126, 2285. This population of stem cells
expresses a higher level of non-cadherin-associated beta.catenin DasGupta, R.; Fuchs, E. Development, 1999, 126,
4557, which may contribute to their high proliferative poten
tial. Moreover, transgenic mice overexpressing a truncated
.beta.-catenin in the skin undergo de novo hair-follicle mor
phogenesis, which normally is only established during
embryogenesis. The ectopic application of GSK3 inhibitors
may therefore be therapeutically useful in the treatment of
baldness and in restoring hair growth following chemo
therapy-induced alopecia. A further aspect of the application
therefore relates to a method of treating a GSK3-dependent
disorder, said method comprising administering to a subject
in need thereof, substituted purine-based triazole, or a phar
maceutically acceptable salt thereof, as defined above in an
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In this example, we synthesized a series of fluorinated
purine-based triazoles and assayed their protective effect
against Af-induced neurotoxicity in hippocampal slice cul
tures. We reasoned that a fluoroaryl group distant from the
nucleoside moiety, through optimal hydrophobic interactions
at the enzyme active site, could impart selective CDK5 inhibi
tory effect, effectively causing neuronal cell cycle Suppres
S1O.
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Selective inhibition of CDK5/p25 over CD5/p35 and other
CDK kinases is a desired goal for the treatment of a number
of CDK dependent disorders, including neurological disor
ders, such as Alzheimer's disease and proliferative disorders,
Such as cancer. Roscovitine is currently undergoing clinical
trials as kinase inhibitor in AD, although it is not a selective
inhibitor of CDK5. Similarly, a flavone-derived compound,
Flavopiridol has also been shown to be effective as a broad
spectrum CDK inhibitor. Perhaps due to this nonspecificity to
selective CDKs, it is more cytotoxic and has other harmful
effects. It is therefore desirable to design selective CDK
inhibitors that show neuroprotective effects, without atten
dant harmful side effects. We anticipated that modulating the
hydrophobicity effect of the compounds by attaching the
fluoroaryl rings to the Roscovitine analogues through 1,2,3triazole linkage might make these compounds selective
inhibitors of CDKs. We adopted Sharpless-Huisgen’s Click
chemistry as a convenient technique for tethering fluorinated
and variously substituted aryl moieties to purine derived
alkynes, and investigated the neuroprotective effects of these
fluoroaryl substituted purine based 1,2,3-triazoles along with
those of Flavopiridol (1) and Roscovitine (2) for AD and
related neurological diseases.
In this Example, we used a convenient assay for neuronal
cell death, which was induced by incubation with A oligo
mers in hippocampal slice cultures. The binding of propidium
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iodide (PI) with DNA of dead cells gives characteristic fluo
rescence that could be followed by fluorescence microscopy.
Since PI is impermeable to live cell membranes, the observed
fluorescence is indicative of the extent of dead cell popula
tions. Using this technique, we have found that incubation of
hippocampal neuronal cells with A? results in significant
neuronal cell death after a duration of 48 h (FIG. 1).
Materials and Methods
Benzylamine (>99.5%), 1-butanol (anhydrous, 99.8%),
benzyl bromide (reagent grade, 98%) triethylamine
(>99.5%), dimethyl sufoxide (ACS reagent, >99.9%), potas
sium carbonate (ACS reagent, >99.9%), Copper(I)bromide
(98%), 2-flurobenzyl bromide (98%), 2,6-difluorobenzylbro
mide (97%), pentafluorobenzylbromide (99%), and 2,6dichloropurine (97%) were obtained from Aldrich and used
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balanced salt solution, 20% heat-inactivated horse serum,

enriched with glucose to a concentration of 5.6 mM. The
medium was changed every other day. Slices were examined
periodically for viability, and any dark or abnormal slices
5

10

15

as received.

"H NMR spectra (400 MHz), ''C NMR spectra (100
MHz), and F NMR spectra (376 MHz) were obtained on a
Varian Inova 400 MHz spectrometer in DMSO-desolutions.
'F NMR spectra were referenced to CFCs (8'F=0), and H,
and 'C NMR were referenced to the residual solvent signals

or internal tetramethylsilane. EI/MS was obtained using solid
probe on a Hewlett Packard HPs 5890 GC/MS instrument.
Computational Methodology
The CDK5 protein structure was obtained from its Rosco
vitine co-crystal PDB entry, “1 UNL, and minimized using
Dreiding force-field. This protein structure was used to first
identify potential ligand binding regions as follows: The
entire protein was scanned for potential binding regions with
no assumption on the binding site. The entire molecular Sur
face of the predicted Structure is mapped and spheres repre
senting the empty volume of the protein are generated (using
the Sphgen program in DOCK4.0 suite of programs). The
entire set of protein spheres is partitioned into ~30 to 50

overlapping cubes of 10 to 14 A sides. The 1000 poses are

generated for each of these 30-50 regions and the results
compared to select the most promising two or three putative
binding regions. This bind site scanning procedure is used for
agonists and antagonists separately with the hypothesis that
an agonist might prefer a site different than an antagonist.
The putative binding regions identified in the above scan
ning procedure were docked with Roscovitine, and com
pounds 7 and 9 separately, using Goddard’s DarwinDock/
GenDock methodology 20 to predict the binding region and
pose preferred by these molecules. The top scoring binding
poses were compared in terms of their pharmacophore and
their relative binding energies.
Preparation of AB Oligomers
1.0 mg of AB1-42 peptide was dissolved in 120 uL of
hexafluoroisopropanol for 60 min at room temperature, and
placed back on ice for 5-10 min. Hexafluoroisopropanol was
evaporated overnight in the hood at room temperature. The
sample was dissolved by 100% DMSO by adding 20 uL of
fresh anhydrous DMSO (Sigma Hybri-Max) to 0.45 mg of the
peptide, and diluted to 5 mM peptide stock into medium.
Diluted peptide was incubated at 4°C. for 24 h, and then
centrifuged at 14,000 g for 10 min in the cold. Before treating
slice culture with A? oligomers, the oligomers were incu
bated at room temperature for 20 h.
Preparation of Hippocampal Slice Cultures
Hippocampal slice cultures were prepared from 7-10 day
old mouse pups. Slices were cut at 400 um on a Mcllwain
tissue chopper, transferred to Millicell (Millipore Corp., Bed
ford, Mass.) membrane inserts (0.4 um), and placed in 6-well
culture plated. The upper surfaces of the slices were exposed
to a humidified 37° C. atmosphere containing 5% CO. Slice
culture media consisted of basal Eagles medium with Earle's
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were discarded.

Experimental Treatment of AB Oligomers to Organotypic
Hippocampal Slice Culture
The effects of AB oligomers were tested in the slices which
had been maintained for 15-20 days in vitro. All reagents
were added to serum free medium (no horse serum). Af
oligomers were added to cultures in serum free medium.
Vehicles were treated the same way except with no peptide.
The slices were pretreated with compounds 6, 7, 8, 9 or cell
cycle inhibitor Flavopiridol or Roscovitine (1 uM) for 1 h
before AB oligomers treatment.
Assessment of Neuronal Cell Death by PI Staining
To analyze the degree of hippocampal neuronal cell death,
hippocampal slices were stained by adding PI into slice cul
ture medium at a concentration of 5ug/mL. At indicated times
after AB oligomers treatment, the degree of hippocampal
neuronal death was evaluated by microscopic observation of
PI uptake as described previously. 23 Images were acquired
through an AxioCam camera on an Axiovert 200M micro
scope (Zeiss, Thornwood, N.Y.). The intensity of the fluores
cence was quantitatively analyzed using Scion Image. The
images were expressed as an arbitrary unit of PI uptake.
Statistical Analysis
Data were expressed as the means-S.E. of the values from
the number of experiments indicated in the corresponding
figures. Differences between groups were examined for sta
tistical significance using one-way analysis of variance with
an unpaired Students t-test. A p value less than 0.05 is denoted
to have statistical significance.
Synthesis of Compounds
2-Chloro-6-benzylaminopurine (4)
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To a suspension of 2,6-dichloropurine (110 mg 0.52
mmol) in n-butanol (3 mL), benzylamine (57 mg, 0.52 mmol)
and triethylamine (72 mg 0.79 mmol) was added. The mix
ture was stirred and heated at 60° C. for 15 min. The resulting
precipitate was filtered, washed with water (20 mL) and
methanol (10 mL), and air-dried overnight. Compound 4 (130
mg, 95%) was obtained as an off-white solid: mp 262° C.;
EI/MS (m/z (relative%)): 259 (19, M), 260 (14), 261 (17%),

106 (100), 91 (77); H NMR (400 MHz, DMSO) & 8.15 (s,
1H), 7.25-7.34 (m, 5H), 4.66 (d. J=6 Hz, 2H); 'CNMR (100
MHz, DMSO) & 155.0 (s) 153.1 (s), 150.7 (s), 140.2 (d.
'J, 200Hz), 139.6(s), 128.5 (d, 'J, -158 Hz, 127.5 (d.
'J -157 Hz), 127.0 (d. J. -158 Hz) 118.1 (s), 43.4 (t,
'J =139 Hz).
2-Chloro-6-benzylamino-9-(2-propynyl)purine (5)
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A solution of 2-chloro-6-benzylaminopurine (1.1 g, 3.8
mmol), in DMSO (5 mL) was cooled to 0°C., potassium
carbonate (0.79 g, 5.7 mmol) and propargyl bromide (0.45 g,
3.8 mmol) was added to the contents, and stirred for 1 h at 0°
C. Water (20 mL) was then added to the reaction mixture, and
the resulting yellow precipitate was filtered and washed with
excess water (50 mL). Compound 5 (1.1 g, 80%) was
obtained as an off-white solid upon Successive recrystalliza
tion from dichloromethane and ethyl acetate: mp 180° C.;
EI/MS (m/z (relative%)): 297 (63, M), 298 (15), 299 (23),

258 (46), 91 (100); H NMR (400 MHz, DMSO) & 8.23 (s,
1H), 7.21-7.38 (m, 5H), 5.03 (bs, 2H), 4.62 (d. J=6 Hz, 2H),
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3.51 (s, 1H). ''C NMR (100 MHz, DMSO) & 155.6 (s),
154.0 (s), 150.3 (s), 140.7 (d, 'J, 214 Hz) 139.9 (s), 128.9
(d, J =159 Hz), 127.9 (d. J. -157 Hz), 126.8 (d.
'J = 158 Hz), 118.1 (s), 78.5 (t, J =9 Hz) 76.7 (dt,
'J 252 Hz, J. 4 Hz), 43.8 (t, J =126 Hz), 33.3
(t, J =139 Hz).

‘J. -19 Hz, J. -6 Hz), 111.8 (t, J -19 Hz) 43.7 (t,
'J =150Hz), 41.4 (t, J =150Hz), 38.6 (t, J =150
Hz).
2-Chloro-6-benzylamino-9-1-(pentafluorobenzyl)1H-1,2,3-triazol-4-yl-methylpurine (9)

Procedure A: Synthesis of 2-Chloro-6-benzylamino
9-(1-benzyl-1H-1,2,3-triazol-4-yl-methyl)purine (6)
10

Benzyl bromide (110 mg, 0.58 mmol) was added dropwise
to a solution of sodium azide (42 mg, 0.64 mmol) in DMSO
(5 mL, and stirred at room temperature for 15 min. Compound
5 (173 mg, 0.58 mmol), triethylamine (6 mg, 0.06 mmol) and
CuBr (8 mg, 0.6 mmol) were added to the contents in that
order, and the reaction mixture was stirred at room tempera
ture for 30 min. The reaction mixture was poured into ice-cold
water (20 mL), and the resulting off-white precipitate was
filtered and washed with dilute NHOH (20 mL) and water
(50 mL) to give the compound 6 (200 mg 80%) essentially
pure by NMR: mp 235° C. EI/MS (m/z (relative%)): 430 (32,
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M"),431 (11),432 (13), 258 (54), (100); H NMR (400 MHz,
DMSO) & 8.23 (s, 1H), 8.15 (s, 1H), 7.40-7.17 (m, 10H), 5.56

(s. 2H), 5.40 (s. 2H), 4.62 (d. J=6 Hz, 2H); 'C NMR (100
'J = 199 Hz), 141.9 (s), 139.9 (s), 136.51 (s), 129.4 (d.
'J -160 Hz), 128.9 (d. J. -159 Hz), 128.8 (d.
'J = 159 Hz), 128.5 (d, 'J, -158 Hz), 127.9 (overlap
ping doublets), 127.4 (overlapping doublets), 124.4 (d.
'J -200 Hz) 118.6 (s), 53.4 (t, J
145 Hz), 43.7 ((t,
'J', -135 Hz), 38.9 (t, J =139 Hz).
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MHz, DMSO) & 155.6 (s), 153.9 (s), 150.3 (s), 143.1 (d.

2-Chloro-6-benzylamino-9-1-(2-fluorobenzyl)-1H
1,2,3-triazol-4-yl-methylpurine (7)
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Compound 7 was obtained as an off white solid (85%),
using procedure A: mp 240° C.; EI/MS (m/z (relative %)):
448 (44, M), 449 (14), 450 (17), 258 (83), 109 (100), 91

(67); H NMR (400 MHz, DMSO) & 8.23 (s, 1H), 8.17 (s,
1H), 743-7.10 (m,9H), 5.60 (s.2H), 5.38 (s.2H), 4.60 (d. J=6
Hz, 2H); 'F NMR (376MHz, CDC1)-117.37 (dd, J=14 Hz,
8 Hz); 'C NMR (100 MHz, DMSO) & 160.7 (d, J =248
Hz), 155.6 (s), 153.8 (s), 150.3 (s), 143.1 (d, J = 199Hz),
142.0 (s), 139.9 (s), 131.4 (d, J =165 Hz) 131.3 (dd.
'J -160 Hz, J-4 Hz), 128.9 (d. J. =156 Hz) 127.9
(d. J. -150 Hz), 127.4 (d, 'J, -160 Hz), 125.5 (d.
'J -150 Hz), 124.5 (d. J. 200 Hz), 123.3 (d.
'J -26 Hz), 118.6 (s), 116.2 (dd, J-170 Hz, J. 21
Hz) 47.6 (t, J =130), 43.8 (t, =133 Hz), 38.9 (t,
J. 143 Hz).

40

45

Results

Synthesis
Referring to scheme 1, described previously, the triazole, 6,
and its fluorinated derivatives, compounds 7-9, were prepared
by the Sharpless-Huisgen’s Cu(I) catalyzed 1,3-dipolar
cycloaddition reactions of the corresponding alkyne and
azide Substrates. As expected, the products show high 1,4regioselectivity in these cycloadditions.
Reaction of the commercially available 2,6-dichloropurine
(3) with benzylamine gave 2-chloro-6-benzylaminopurine
(4) using a reported procedure. Under our conditions, the
reaction was complete in 15 min at 60° C. instead of the
reported time of 3 hat 110°C. Propargylation of compound 4
using propargyl bromide in DMSO under mild conditions
gave 2-chloro-6-benzylamino-9-(2-propynyl) purine (5)
regioselectively in high yield. The Cu(I) catalyzed azide
alkyne click reaction (the Sharpless-Huisgen 1,3-dipolar
cycloaddition) of the alkyne 5 with fluorinated benzyl azides,
prepared in situ from their corresponding benzyl bromides,
gave exclusively 1,4-disubstituted triazoles, 7-9. The iso
meric homogeneity of the product triazoles was readily veri
absorptions as compared to the o-fluorophenylmethyl- and
the 2,6-difluorophenylmethyl-triazoles, 7 and 8 respectively,
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Compound 8 was obtained as an off white solid (84%),
using the procedure A: mp 239°C.; EI/MS (m/z (relative%)):
466 (52, M), 467 (19), 468 (22), 258 (77), 127 (100), 91

(73); H NMR (400 MHz, DMSO) & 8.20 (s), 8.16 (s), 7.05
5.5
Hz, 2H), F NMR (376 MHz, CDC1) 8-114.10: CNMR
(100 MHz, DMSO) & 1614 (dd, J =248 Hz, J =7
Hz), 155.5 (s), 153.8 (s), 150.3 (s), 143.01 (s), 142.03 (d.
'J = 199 Hz), 139.9 (s), 132.4 (dt, J =166 Hz,
J. -10 Hz), 128.9 (dd, J =159 Hz, J. -6 Hz),
127.9 (dim, 'J, -154 Hz), 127.5 (d, 'J, -164 Hz), 124.6
(d. J. -197 Hz), 118.6 (s), 112.6 (ddd, J =166 Hz,

(64), 91 (100); H NMR (400 MHz, DMSO) & 8.22 (s, 1H),
8.23 (s, 1H), 7.32-7.19 (m, 5H), 5.73 (s. 2H), 5.39 (s. 2H),
4.61 (d. J. =5.5, 2 H); 'F NMR (376 MHz, CDC1) &
-141.70 (dd, 'J, -23.2, J –7.2 Hz, ortho-fluorines),
-152.7 (t, J =22 Hz, para-fluorine), —161.43 (dt,
'J 22.9, J =7.4 Hz, meta-fluorines); 'C NMR (100
MHz, DMSO) & 155.5 (s), 153.8 (s), 150.3 (s), 145.6 (dim,
'J -254 Hz), 143.14 (s), 142.01 (d. J. -199Hz), 141.6
(dim, 'J, -259 Hz), 137.7 (d, 'J, 249 Hz), 139.9 (s),
128.9 (dd, J =159 Hz, J. -6 Hz), 127.9 (dim,
'J -154 Hz), 127.5 (d, 'J, -164 Hz), 124.8 (d.
'J =197 Hz.), 118.8 (s), 109.8 (t, J -18 Hz), 43.8 (t,
'J =139 Hz.), 41.1 (t, J =130 Hz), 38.8 (t,
'Jc. 142 Hz).

fied through their 'F NMR spectra. The pentafluorophenyl
methyl-triazole, 9, showed relatively shielded 8F

2-Chloro-6-benzylamino-9-1-(2,6-difluorobenzyl)1H-1,2,3-triazol-4-yl-methylpurine (8)

7.47 (m, 8H), 5.60 (s. 2H), 5.37 (s. 2H), 4.61 (d. J.

Compound 9 was obtained as an off white solid (89%),
using the procedure A: mp 225°C.; EI/MS (m/z (relative%)):
520 (24%, M), 521 (6), 522 (9%), 258 (73), 181 (69), 106
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in accordance with similar observations for the monofluoro-,

difluoro-, and pentafluorotoluenes.
A? has been known to overactivate CDK5 which results in
the tau-hyperphosphorylation, and cell cycle re-entry, leading
to neuronal apoptosis. Thus, we used AB oligomers as the
trigger of neurotoxicity in vitro for convenient assay of the
neuroprotective effects of the kinase inhibitors.
Mouse hippocampal slice cultures were treated with Af
oligomers in the presence of PI as the staining agent. The
degree of hippocampal neuronal death was monitored by
fluorescence microscopic observation of the PI uptake. The
intensities of the fluorescence were conveniently analyzed
using Scion images. The intensity of the PI fluorescence
reflects the relative number of the dead cells, since PI cannot
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permeate the live cell membranes. As shown in FIGS. 1-2,
there is visible difference in the control (in the absence of AB
oligomers) and the AB oligomers-treated cell cultures. Typi
cally 48 h is required for the expression of the AB toxicity.
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These experiments were repeated using the established cell
cycle inhibitors, Roscovitine, Flavopiridol, and the triazoles,
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neurological disorders. Indeed, Darwin Dock/GenDock
docking calculations show that the Roscovitine and the tria
6, 7, 8, and 9.
Zoles 7 and 9 all bind at the same active site region of the
CDK5/p25 complex, with relative binding affinities of -48.1
As can be seen in FIGS. 3-4, after 48 h of incubation time,
Roscovitine, Flavopiridol and the o-fluorophenylmethyl-tria kcal/mol, -44.8 kcal/mol, and -33.3 kcal/mol, respectively.
Zole, compound 7, have neuronal cell Survival rates compa The comparable neuroprotective effects of Roscovitine and
rable to those of the control experiments, i.e., those corre compound 7 are thus reflected in their similar binding affini
sponding to the cultures in the absence of the AB oligomers. ties, whereas the unfavorably low binding affinity for com
Interestingly, the pentafluorophenylmethyl-triazole (9) has pound 7 makes it practically inefficient neuroprotector. These
virtually no neuroprotective effect, and the 2,6-difluorophe 10 docking simulations also support the involvement of the
nylmethyl-triazole (8) and the nonfluorinated-analogue (6) CDK5/p-25 complex in the cell cycle re-entry, a leading cause
have only marginal effects. Thus the degree of fluorination of the neuronal degeneration.
has a dramatic effect on the neuroprotective effects of these
From the above description of the invention, those skilled
compounds, implying that these compounds may serve as in the art will perceive improvements, changes and modifica
substrates for CDK5/p25 complex which is responsible for 15 tions. Such improvements, changes, and modifications are
the cell cycle re-entry, eventually leading neuronal cell death. within the skill of the art and are intended to be covered by the
The neurotoxicity of AB peptide may arise primarily due to appended claims. All patents and publications identified
its overactivation of CDK5/p25 complex followed by cell herein are incorporated by reference in their entirety.
cycle re-entry. Thus, selective enzyme inhibitors for CDK5/
described the invention, the following is claimed:
p25 are the ideal target for designing state of the art neuro- 20 Having
1. A compound of formula I
protective agents. Goddard’s state of the art molecular dock
ing methods, Darwin Dock/GenDock, are ideally suited in the
design of these selective inhibitors. We have shown the valid
(I)
ity of these calculations for CDK5/p25 by reproducing the
N
Roscovitine/CDK5-p25 cocrystal structure from protein data 25
bank (PDB; 1UNL). We have located three potential binding
regions (A, B, and C: FIGS. 5-6) in CDK5/p25 and showed
that all high scoring poses preferred Region A which is con
sistent with the binding site observed in the co-crystal, 1UNL.
In addition, the binding pose is within 0.17 A (heavy atom 30
RMSD) of the pose observed in the co-crystal structure
or a pharmaceutically acceptable salt thereof,
(1UNL). The predicted structure superimposed on the experi
mental co-crystal structure (1UNL) is shown in FIG. 4.
where R is a hydrophobic, substituted or unsubstituted,
aryl, cyclic, or heterocyclic group;
Docking of Compounds 7 and 9 to the three potential
ligand binding regions predicts that these inhibitors also pre 35 where R and R independently represent substituents
Selected from the group consisting of hydrogen, halo
fer region A. The closeup view of the binding site for com
gen, C1-C4 alkyl, C2-C2a alkenyl, C2-C2a alkynyl,
pound 7 is shown in FIG. 7. The later site overlaps the Ros
Cs-Co aryl, C-C2a alkaryl, C-C2a aralkyl, silyl,
covitine site but the molecule has a different pose and
hydroxyl, Sulfhydryl, C-C alkoxy, C-C alkeny
interacts strongly with a different set of CDK5 residues
loxy, C-C alkynyloxy, Cs-Co aryloxy, acyl, C-C
except for Gln130. It shows three strong H-bonding interac 40
alkylcarbonyl (—CO-alkyl). Co-Co arylcarbonyl
tions with Asn144, Lys89, backbone carbonyl of Ile10, and
(—CO-aryl)), acyloxy (—O-acyl), C-C alkoxycarbo
relatively weaker interaction with Gln130.
nyl (-(CO)—O-alkyl). Co-Co aryloxycarbonyl
Compound 9 shows the same binding pose as Compound 7.
(—(CO)—O-aryl), C-C alkylcarbonato (-Oas expected from the structural similarities. The relative bind
(CO)—O-alkyl). Co-Co arylcarbonato ( O—(CO)—
ing energies for Roscovitine, and compounds 7 and 9 are 45
O-aryl), carboxy ( -COOH), carboxylato (-COO),
-48.1 kcal/mol, 44.8 kcal/mol, and -33.3 kcal/mol, respec
carbamoyl (—(CO)—NH), mono-(C-C alkyl)-sub
tively, which correlates well with the PI assay. The similar
binding energies for Roscovitine and compound 7 are in
stituted carbamoyl (—(CO)—NH(CC alkyl)), di
accordance with their comparable neuroprotective effects
(C-C alkyl)-substituted carbamoyl (—(CO) N(C.
C
alkyl)), mono-Substituted arylcarbamoyl
(FIG. 2), whereas the much lower binding energy for the 50
(—(CO). NH-aryl), thiocarbamoyl (—(CS) NH),
compound 9 is consistent with its ineffectiveness in enzyme
binding observed in our experiments (FIG. 2). The difference
carbamido ( NH (CO) NH), cyano( CN), iso
in binding energies for compounds 7 and 9 comes mainly
cyano (—NC), cyanato (-O-CN), isocyanato
from the larger desolvation penalty needed to bury the pen
(O—NC), isothiocyanato ( S. NC), azido ( N=N*
tafluorophenyl group of Compound 9 as compared to the 55
—N), formyl (—(CO)—H), thioformyl ( (CS)—H),
o-fluorophenyl group of compound 7. This desolvation pen
amino ( NH), mono- and di-(C-C alkyl)-substi
tuted amino, mono- and di-(Cs-Co aryl)-substituted
alty difference, calculated using an implicit Solvation model
amino, C-C alkylamido (—NH-(CO)-alkyl).
(Poisson-Boltzmann), is about 9 kcal/mol and accounts for
Co-Co arylamido (—NH-(CO)-aryl), imino, alky
most of the reduction in binding energy of compound 9.
In summary, we have found that our o-fluorophenylmethyl 60
limino, arylimino, nitro ( NO), nitroso ( NO), Sul
derived triazole, 7, effectively suppressed AB-induced neuro
fonic acid ( SO, OH), sulfonato ( SO. O.),
C-C alkylsulfanyl ( S-alkyl), arylsulfanyl, C-C
toxicity in hippocampal slice cultures, while the pentafluoro
alkylsulfinyl (—(SO)-alkyl), Cs-Co arylsulfinyl
aryl derived triazole 9 has virtually no neuroprotective effect
(—(SO)-aryl), C-C alkylsulfonyl (-SO-alkyl).
Importantly, the neuroprotective effect of compound 7 is
Cs-Co arylsulfonyl ( -SO-aryl), phosphono ( -P(O)
comparable to Flavopiridol and Roscovitine, state of the art 65
pharmaceuticals. These results suggest our newly synthe
(OH)2), phosphonato (-P(O)(O—)), phosphinato
(—P(O)(O)), phospho (—PO), and phosphino
sized compound 7 as a therapeutic candidate for AD and other
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(—PH), and where each RandR, being independently
unsubstituted or substituted where appropriate by one or
more —OH, halogen, amino or alkyl groups.
2. The compound of claim 1, where R1 is a fluorinated aryl,
cyclic, or heterocyclic group.
3. The compound of claim 1, where R and Rs are each
independently a hydrogen, a halogen, C1-C4 alkyl, C2-C24
alkenyl, C-C alkynyl, C-Co aryl, C-C alkaryl, C-C,
aralkyl, or an R. NH , R. NH-NH NH R'
NH or R. NH R NH radical, in which Ra repre
sents a straight- or branched-chain, Saturated or unsaturated
alkyl radical, an aryl or cycloalkyl radical or a heterocyclic
ring and R' represents a straight- or branched-chain, Saturated
or unsaturated alkylene group or an arylene or cycloalkylene
group, R4 and R' each containing 1 to 8 carbon atoms, and
where each R and R being independently unsubstituted or
substituted, where appropriate, by one or more —OH, halo
gen, amino or alkyl groups.
4. The compound of claim 1 having the formula (II):
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5. The compound of claim 1, having the formula (III)
(III)
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Or )--e S-C
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(II)

N

N

N-4,

25

( )-

'-ty--30

or a pharmaceutically acceptable salt thereof,
where X is a halogen;
where n is an integer from 0-5:
where n is an integer from 1-3:
where Y is substituted or unsubstituted C-C alkyl,
C-C alkenyl, C-C alkynyl, C-Co aryl, C-C,
alkaryl, C-C2a aralky; and
where R is a hydrogen, a halogen, C-C alkyl, C-C,
alkenyl, C2-C alkynyl, Cs-Co aryl, C-C alkaryl,
C-C aralkyl, or an R. NH-, R. NH-NH-.
NH R NH or R. NH R NH- radical, in
which R represents a straight- or branched-chain, Satu
rated or unsaturated alkyl radical, an aryl or cycloalkyl
radical or a heterocyclic ring and R' represents a straight
or branched-chain, Saturated or unsaturated alkylene
group or an arylene or cycloalkylene group, R and R'
each containing 1 to 8 carbon atoms, and where R is
unsubstituted or Substituted, where appropriate, by one
or more —OH, halogen, amino or alkyl groups. In one
example, R is hydrogen, Cl, F, an alkyl or substituted
alkyl.
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or a pharmaceutically acceptable salt thereof,
where n is an integer from 0-5; and ortho-, meta- and
para-isomers,
where R2 is a hydrogen, a halogen, C1-C4 alkyl, C2-C24
alkenyl, C-C alkynyl, C-Co aryl, C-C alkaryl,
C-C aralkyl, or an R. NH , R. NH-NH-,
NH R NH or R. NH R NH- radical, in
which R represents a straight- or branched-chain, Satu
rated or unsaturated alkyl radical, an aryl or cycloalkyl
radical or a heterocyclic ring and R' represents a straight
or branched-chain, Saturated or unsaturated alkylene
group or an arylene or cycloalkylene group, R and R'
each containing 1 to 8 carbon atoms, and where R is
unsubstituted or Substituted, where appropriate, by one
or more —OH, halogen, amino or alkyl groups.
6. The compound of claim 1, where R2 is C1, F, an alkyl or
substituted alkyl.
7. A pharmaceutical composition comprising a compound
according to claim 1, admixed with a pharmaceutically
acceptable diluent, excipient, carrier or mixtures thereof.
8. A method for promoting neuron Survival in the presence
of amyloid B, the method comprising:
administering to a neuron in the presence of amyloid B a
therapeutically effective amount of a compound accord
ing to claim 1.
9. A method for treating a neurological disorder wherein
the neurological disorder is Alzheimer's disease in a Subject,
the method comprising:
administering to the subject a therapeutically effective
amount of a compound according claim 1, and a phar
maceutical carrier.
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10. The method of claim 9, the neurological disorder being
mediated by amyloid B.
11. The method of claim 9, the compound being adminis
tered at an amount effective to promote neuronal Survival.
k
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